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paraventricular nucleus and secrete TRH into the pericapillary space of the external
zone of the median eminence for conveyance to anterior pituitary thyrotrophs.  Under
basal conditions, the activity of hypophysiotropic TRH neurons are regulated by the
negative feedback effects of thyroid hormone to ensure stable, circulating, thyroid
hormone concentrations, a mechanism that involves complex interactions between
hypophysiotropic TRH neurons and the vascular system, CSF and specialized glial
cells called tanycytes.  Hypophysiotropic TRH neurons also integrate other humoral
and neuronal inputs that can alter the setpoint for negative feedback regulation by
thyroid hormone.  This mechanism facilitates adaptation of the organism to changing
environmental conditions, including the shortage of food and a cold environment.  The
thyroid axis is also affected by other adverse conditions such as infection, but the
central mechanisms mediating suppression of hypophysiotropic TRH may be
pathophysiologic.  In this review, we discuss current knowledge about the mechanisms
that contribute to regulation of hypophysiotropic TRH neurons under physiological and
pathophysiological conditions.
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manuscript (# ER-13-1087) entitled “Central regulation of the hypothalamic-pituitary-
thyroid axis under physiological and pathophysiological conditions” by Csaba Fekete, and 
Ronald M. Lechan
 
for reconsideration as a publication in Endocrine Reviews.  Changes in the 
manuscript and responses to the Reviewers’ criticisms are detailed below under each 
reviewer. 
 
Reviewer 1: 
Point 1: The authors may want to add a short paragraph on the neuroanatomy and possible 
physiologal role of the autonomic innervation…. 
Response:  We added a new section to address the autonomic regulation of HPT axis. 
Point 2: V, p. 35. First sentence: "DIA is an interesting model...". The authors should add for which 
particular process/function DIA is a model. 
Response:  We altered the first paragraph of Section V to better describe this model. 
Point 3: VIII. p.41, Cold exposure triggers TRH gene expression in the PVN; the authors discuss the 
likely role for brainstem catecholaminergic neurons in this response. However, it is unclear what the 
effect/relevance of this TRH response might be, ….. 
Response: We now discuss the potential relevance of the cold-induced ,transient hyperthyroidism in 
the regulation of thermogenesis.  We also discuss why we think that the hypophysiotropic TRH 
neurons do not influence BAT via the ANS. 
Point 4: P 16: The text on alpha 1 and alpha 2 tanycytes (lines 8-14) does not match with Fig 7B. 
Response: We corrected this error in Figure 7. 
Reviewer 2: 
Point 1: P13 The sentence concluding the second paragraph ? ; ' different role in the regulation of the 
thyroid axis in humans »  begs the question about the role of CART innervation to the these neurons 
in regulating feeding in humans and should be clarified. 
Response: The CART innervation of TRH neurons has not been studied in the human hypothalamus, 
and even more importantly, due to the serious side effects of CART and the lack of CART agonists or 
antagonists, it is not possible to perform human experiments to determine the role of CART in the 
regulation of TRH neurons.  However, the fact that CART is expressed in a number of different 
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neuronal populations in the human hypothalamus compared to rodents is enough to  be concerned 
that the rodent findings may not necessarily be true for humans. 
Point 2: P15 para1, I don't like the idea that « transmitters interact with each other. ».  The 
molecules don't interact. I think it should be better expressed in terms of the crosstalk between 
effector systems. 
Response: We modified this sentence. 
Point 3: P15 para 2 : specify with species is being referred to for the ref 83. 
Response: We now specify that these data originate from experiments performed in rats. 
Point 4: P 15 para 3 a number of the inputs listed as additional - have already been mentioned - 
GABA , PACAP and glutamate. Rewrite for precision. 
Response: We corrected this sentence. 
Point 5: Pp 22 and 18 are a bit contradictory in that on p18 we're told that that (end of para 1) that « 
most of the regions of the hypothalamus are devoid of D2 » and  then on P22 para 1 lines 4-5 that «  
D2 is also regulated in the hypothalamus at the transcriptional level ». Correct / clarify please. 
Response: We changed the mentioned sentence on page 22.   
Point 6: P 20 - To my school of thought 'why' is not a correctly formulated biological question and 
implies teleology or « purpose » that has no place in current evolutionary theory. The question 
should be termed in the light of redundance versus specificity.  In fact the observations that in many 
other brain areas TRb1 and TRa1 coxist and coregulate common targets is not considered aberrant - 
but indeed taken as examples of redundancy and this is no doubt the case for the similar effects of 
B1 and B2 discussed here. 
Response: We changed the mentioned sentence. 
Point 7: P 23 - section on transporters. This part could be usefully reorganised slightly bringing the 
idea of active transport to the start ( the sentence beginning « Despite their lipophilic?. »)  - so that 
the verb 'extract' makes more  sense. 
Response: We reorganized this part according to the Reviewer’s suggestion. 
Point 8:  P24 explain what is meant by 'volume transmission', not obvious. 
Response: To clarify this point, we now use the term “diffusion”. 
Point 9:  Similarly at the end of this paragraph the idea that only hypophysiotroic TRH neruons are 
affected by changed peripheral TH levels is not only prompted by the previous question ( how T3 
reaches the TRH neurons) and the proposed hypothesis - and discussion of this point really needs 
some highlighting/ more detail of potential hypothesis that could be testable. 
Response: We added the following sentence to the end of the paragraph: “However, further 
studies are needed to demonstrate that the T3 content of hypophysiotropic and non-
hypophysiotropic TRH neurons is differentially regulated by changes in peripheral thyroid 
hormone levels.” 
Point 10:  P 29 and 31 - repetition of the idea that lack of NPY and MC4R abrogate fasting induced 
drop in T3 
Response: The reviewer is correct that the data is mentioned in two parts of the manuscript.  
However, we use these data to support the importance of the the arcuato-paraventricular pathway 
in the regulation of TRH neurons during fasting on page 29, whereas on page 31 we use the data to 
demonstrate that the direct effect of leptin on the TRH neurons seems to have negligible effect 
during fasting despite of the well documented direct action of leptin on these cells.  Therefore, 
repetition of the data on both places is of particular importance.    
Point 11:  Not clear what the overall hypothesis is that is being discussed end P 32 / para 1 p 33. 
Response: We added a sentence at the beginning of this section to resolve the problem. 
Point 12:  P 36 - suddenly start talking about POMC neurons - well most will know that POMC is 
processed into aMSH etc - but given that many readers will be new to the area ( see point 1) then 
this needs to be explained? 
Response: We changed the sentence to clarify that proopiomelanocortin (POMC) is the precursor of 
α-MSH. 
Point 13:  the discussion of non-critical illness might require some better explanation of the current 
ideas of 'acute' versus 'prolonged' phases as the therapeutic options differ dramatically according to 
the phase (Van den Berge's recent data). 
Response: The Reviewer is correct that the nonthyroidal illness has been separated by some authors 
into acute and chronic phases.  This distinction has been dealt with extensively in a previous 
Endocrine Reviews article published by Boelen et al in 2011.  The acute phase is largely believed to be 
secondary to decreased conversion of T4 to T3 in peripheral tissues (liver, muscle, adipose tissue) 
due to changes in deiodinases, whereas the chronic phase involves changes both in both the 
periphery and in the central nervous system.  We suspect that central changes are occurring during 
the acute phase, but this has not been systematically studied.  
Point 14:  Indeed this section (VII) that leads into translational ramifications (IX) (after a short section 
on cold)  is rather superficial and disappointing . Translational aspects of TRH physiology are by no 
means limited to this pathology. So if there is one area of the reveiw that merits more effort from the 
authors and a rewrite this is it. 
Response: We changed the Translational ramification Section. 
Response to minor points: As recommended, we expanded this section.. 
Reviewer 3: 
Point 1: It is well written but suffers from too much detail in some areas and not enough in others.  
First, the focus on the hypothalamic TRH neurons is appropriate but much of the material is the 
authors' own view of the how the TRH neuron is regulated. 
Response: The authors made a concerted effort to include all data that are related to the reviewed 
topics.  If there are areas that have not been covered in sufficient detail, it would be helpful to know 
specifically what those are so we can make the appropriate changes.   As noted by the above 
Reviewer, the detail is helpful to allow the reader to best understand the material. 
Point 2: I would recommend eliminating many of the darkfield mRNA figures.  Many appear to be 
previously published or too detailed for the general reader.  
Response: We believe that the darkfield images will help the readers to better understand the topic, 
therefore, we would like to retain these images. 
Point 3:  The structure of the TRH gene also adds little to the review.   
Response: The goal of the manuscript is to summarize  current knowledge about the function and 
regulation of hypophysiotropic TRH neurons.  The regulation of TRH gene expression is a critical 
component and it’s understanding  highly facilitated by the description of the structure of TRH gene. 
Therefore, we wish to retain this part of the manuscript and the figure that supports it. 
Point 4:  What would be helpful are figures that present how the HPT is regulated by multiple 
pathways such as by feeding, fasting, thyroid hormone, etc. 
Response: Fig 10 and 12 summarize the regulation of the TRH neurons by feeding and fasting and by 
thyroid hormones,respectively. 
Point 5  Finally, the authors argue that in vivo data in TR KO animals are somehow equivalent to in 
vitro studies of TR over-expression in non-homologous cells.  I would suggest rewriting those 
sections. 
Response: The only in vitro data mentioned in that part of the manuscript is the effect of T3 on 
hypothalamic cell culture in its early stage when the predominant TR in the cells is TRα.  We did not 
consider these data equal with the knock out studies, but do feel that the cell culture data support 
the in vivo findings.  Therefore, we wish to retain this Section in the current form. 
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Abstract 
    Thyrotropin-releasing hormone (TRH) is a tripeptide amide that functions as a 
neurotransmitter, but also serves as a neurohormone that has a critical role in the central 
regulation of the hypothalamic-pituitary-thyroid (HPT) axis.  Hypophysiotropic TRH neurons 
involved in this neuroendocrine process are located in the hypothalamic paraventricular 
nucleus and secrete TRH into the pericapillary space of the external zone of the median 
eminence for conveyance to anterior pituitary thyrotrophs.  Under basal conditions, the 
activity of hypophysiotropic TRH neurons are regulated by the negative feedback effects of 
thyroid hormone to ensure stable, circulating, thyroid hormone concentrations, a mechanism 
that involves complex interactions between hypophysiotropic TRH neurons and the vascular 
system, CSF and specialized glial cells called tanycytes.  Hypophysiotropic TRH neurons also 
integrate other humoral and neuronal inputs that can alter the setpoint for negative feedback 
regulation by thyroid hormone.  This mechanism facilitates adaptation of the organism to 
changing environmental conditions, including the shortage of food and a cold environment.  
The thyroid axis is also affected by other adverse conditions such as infection, but the central 
mechanisms mediating suppression of hypophysiotropic TRH may be pathophysiologic.  In 
this review, we discuss current knowledge about the mechanisms that contribute to regulation 
of hypophysiotropic TRH neurons under physiological and pathophysiological conditions.  
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I. Introduction 
    The hypothalamic-pituitary-thyroid (HPT) axis primarily functions to maintain normal, 
circulating levels of thyroid hormone that is essential for the biologic function of all tissues 
including brain development, regulation of cardiovascular, bone and liver function, food 
intake and energy expenditure among many others (1).  Key to this regulatory system are a 
group of neurons that reside in the hypothalamic paraventricular nucleus (PVN), produce 
thyrotropin-releasing hormone (TRH) and integrate a wide variety of humoral and neuronal 
signals to regulate the HPT axis.  In the present review, we will summarize current knowledge 
about the anatomy and physiology of these so called “hypophysiotropic” TRH neurons 
involved in the central regulation of the HPT axis under physiological and specific, 
pathophysiological conditions.  
 
II. Organization of the central machinery regulating the hypothalamic-pituitary-thyroid 
axis 
a. Thyrotropin-releasing hormone (TRH) as a central regulator of the hypothalamic- 
pituitary-thyroid axis 
    TRH is a tripeptide amide (pGlu-His-ProNH2) (2) discovered simultaneously by the groups 
of Schally and Guilleman in 1969 (3, 4).  In these pioneering studies, extracts from more than 
250,000 porcine or sheep hypothalami containing only a few milligrams of TRH was shown 
to have TSH releasing activity.  The extracted material contained only three amino acids: 
glutamic acid, histidine and proline (2), and subsequently was shown to require cyclization of 
the glutamyl residue and amidation of the proline residue to achieve TSH releasing activity 
(2).  
    TRH regulates the synthesis, release and biological activity of TSH (5-7).  This effect is 
mediated via the type 1 TRH receptor (TRHR1) (8).  At first, TRH stimulates the release of 
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presynthesized TSH (6), and then increases the synthesis of both TSH subunits, the α-
glycoprotein hormone subunit (α-GSU), common to all three glycoprotein hormones of the 
anterior pituitary, and the TSH-specific β subunit (5).  Binding of TRH to TRHR1 results in 
activation of phospholipase C, calcium mobilization and activation of protein kinase C.  This 
cascade leads to the synthesis of α-GSU through effects on the pituitary LIM homeodomain 
factor (P-LIM), cAMP response element binding protein (CREB) and CREB binding protein 
(CBP) transcription factors (5).  In contrast, the synthesis of the TSH-β subunit is mediated by 
the pituitary specific transcription factor-1 (Pit-1) and CBP transcription factors (5).  TRH 
also has important role in regulating the glycosylation of TSH by altering the oligosaccharide 
composition and structure of its 3,N-linked carbohydrate chains, important for the folding, 
assembly, secretion, metabolic clearance and ultimately increasing the biological activity of 
TSH (6, 9-11).  Indeed, TRH deficiency in both mouse models and man results in decreased 
TSH bioactivity and low peripheral thyroid hormone levels (12, 13). 
 
b. Molecular characterization of the TRH gene 
    The first partial sequence of the preproTRH gene was cloned from frog skin by Richter et 
al. (14), and the nearly full length cDNA of preproTRH isolated from rat hypothalamic λgt11 
library (15).  A single copy of the preproTRH gene is present in the rat (chromosome 4), 
mouse (chromosome 6) and human (chromosome 3) genomes (16-19).  The structure of the 
rat preproTRH gene is summarized in Figure 1.  In all species, the gene contains three exons 
and two introns (16).  In rats, the size of the introns are 750 and 450 base pairs, respectively 
(16).  The first exon encodes the 5’ untranslated region of the mRNA, and the second exon 
encodes the signal peptide and a portion of the amino terminus of the proTRH peptide.  The 
third exon encodes the remaining part of the amino-terminal peptide, five copies of the TRH 
sequence separated by non-TRH peptide sequences and the carboxyl terminal peptide 
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followed by the 3’ untranslated region of the mRNA (16).  The promoter of the gene contains 
a TATA box 28 base pairs upstream of the transcriptional initiation site (16).  In addition, a 
series of regulatory elements has been identified in the proximal promoter of the gene.  The 
human preproTRH gene contains three, negative, thyroid hormone response elements (TRE) 
(20).  The so called “site 4” is located -55 to -60 base pairs from the transcriptional initiation 
site.  This thyroid hormone receptor (TR) binding half site binds both thyroid hormone 
receptor (TR) homodimers and TR-retinoid X receptor (RXR) heterodimers (20-22).  Two 
other functional TREs are present in the first exon between +14 - +19 and +37 - + 42, 
respectively (20).  These sites can only bind TR monomers, but are also necessary for the 
regulation of the gene by thyroid hormone (20).  Site 4 of the human preproTRH gene is also 
thought to function as a cAMP response element (CRE), resulting in competition between 
cAMP and TR for binding (23, 24).  In the rat preproTRH gene, however, site 4 does not bind 
cAMP and functions exclusively as a TRE (21).  A CRE-2 site identified 5’ to site 4 at -101 to 
-94 seems to function as the primary cAMP response element in this gene (21).  
Glucocorticoid response element (GRE), activator protein 1 (AP-1), Krüppel-like factor 4 
(Klf4), SP1 and STAT3 binding sites have also been identified in the proximal promoter of 
the preproTRH gene (21, 24, 25). 
 
c. Processing of preproTRH  
    The 26 kDa rat preproTRH protein is composed of 255 amino acids (26).  The N-terminal 
25 amino acids comprise the signal peptide that directs the newly synthesized protein into the 
lumen of the rough endoplasmic reticulum (RER) after its synthesis on ribosomes (26).  This 
sequence is cleaved during the passage into the RER (27), leaving a proTRH protein that 
contains 5 copies of TRH progenitor sequences, Gln-His-Pro-Gly, four non-TRH peptides 
located between the TRH progenitor sequences, and C-terminal and N-terminal flanking 
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peptides (27).  The proTRH protein of other species also contains multiple copies of TRH 
progenitor sequences (27), 6 copies in the human and 7 copies in the frog (27).  TRH 
progenitor peptides are flanked by paired basic amino acids, Lys-Arg or Arg-Arg, that serve 
as signals for endoprotease enzymes (27).  The N-terminal flanking peptide is further cleaved 
at the pair of Arg amino acids located in the 51-52 position of the preproTRH molecule.  
Therefore, the processing of the rat proTRH results in 5 copies of TRH and 7 non-TRH 
peptides (27).  Since the non-TRH peptide located between the 4
th
 and 5
th
 TRH progenitors 
can be further cleaved, and incomplete processing at Arg-Arg residues following the 3
rd
 and 
4
th
 TRH progenitor sequences can lead to C-terminally extended TRH peptides (27, 28), the 
actual number of peptides derived from proTRH processing can be even higher.  In addition 
to mature TRH, other proTRH derived peptides such as proTRH 160-169 and proTRH 177-
199, also have biological activity (27).  Therefore, the large number of peptides derived from 
proTRH and evidence for differential processing of proTRH in different regions of the brain 
may serve to increase the diversity of how TRH neurons influence their targets.  
    The cleavage of proTRH at paired basic amino acid residues is primarily performed by two 
enzymes, prohormone convertase 1/3 (PC1/3) and prohormone convertase 2 (PC2) (27).  
However, both PC enzymes can cleave proTRH at multiple sites.  In PC1/3 KO mice, the 
concentration of the TRH tripeptide is reduced by almost 80%, but only by 44% in PC2 KO 
mice.  Therefore, PC1/3 may be more important in the processing of TRH (29).  The lack of 
PC2 has more profound effects on the concentration of some of the non-TRH proTRH 
peptides (29).  After cleavage, the basic amino acid residues are removed by carboxipeptidase 
E (CPE) (27). The TRH progenitor, Gln-His-Pro-Gly, is then amidated by peptidylglycine 
alpha amidating monooxygenase (PAM) using the C-terminal glycine as amide donor (27).  
Finally, the N-terminal glycine is cyclized to pyroglutamate (27), catalyzed by N-glutaminyl 
cyclase (30), resulting in the mature form of TRH. 
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    The processing of the proTRH protein takes place in the trans-Golgi network (TGN) and in 
the regulated secretory pathway (RSP) (27).  The first cleavage of proTRH occurs in the TGN 
(27) where PC1 processes the prohormone at the second or third TRH precursor resulting in a 
9.5 kDa or 15 kDa N-terminal peptide and a 16.5 kDa or 10 kDa C-terminal, intermediate 
peptide (27).  This initial cleavage is also critical for the targeting of proTRH-derived peptides 
into the regulated secretory pathway and the appropriate sorting of these peptides into 
secretory vesicles (31).  After completion of the initial cleavage, the N- and C-terminal 
peptides of proTRH are sorted into different vesicles of the regulated secretory pathway (31). 
Prevention of the initial cleavage by mutation of the paired basic residues, however, directs 
proTRH protein into the constitutive secretory pathway (31).  The C-terminal intermediate 
protein is further cleaved in the TGN at residues 201-202, but all other cleavage steps and the 
maturation of the TRH precursor takes place in the immature and mature secretory vesicles 
(31).   
 
d. Inactivation of TRH 
    Inactivation of secreted TRH in the brain is primarily catalyzed by a membrane-bound 
ectoenzyme, pyroglutamyl peptidase II (PPII) (32-34).  PPII is a type II integral membrane 
protein comprised of a small, N-terminal, intracellular region and a large, extracellular 
domain containing the active site of the enzyme (32).  PPII has stringent substrate specificity 
as it can only degrade peptides that are no longer than 4 amino acids with a pGlu-His-X 
structure, where X can be Pro, Ala, Trp, Pro-NH2, Pro-Gly or Pro-β-NA (32).  PPII produces 
the dipeptide, His-ProNH2, from TRH, which is further degraded by dipeptidyl 
aminopeptidase IV, or spontaneously cyclizes to His-Pro-diketopiperazine (32).  PPII activity 
can be detected in most brain regions where the axons of TRH neurons terminate, but some 
mismatch is observed (32).  PPII is primarily synthesized by neurons, but it is also produced 
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by tanycytes, a specialized glial cell type, in the hypothalamus (32, 35).  Inhibition of PPII 
activity markedly increases the amount of TRH released from brain tissue slices, supporting 
the importance of this peptidase in the metabolism of TRH (32).  
    In serum, TRH is degraded by a soluble enzyme that was formerly called thyroliberinase 
(35), but subsequently shown to be a product of the PPII gene produced in the liver by 
proteolytic cleavage of membrane bound PPII (36).  Two, broad specificity cytosolic 
peptidases, pyroglutamyl peptidase I and prolyl endopeptidase, can also degrade TRH.  
However, as there is no evidence for the presence of these enzymes in the extracellular space 
and only a small proportion of the extracellular TRH is internalized, these enzymes do not 
play a major role in the inactivation of released TRH (32).   
 
e. Anatomical characteristics of hypophysiotropic TRH neurons 
    TRH-synthesizing neurons are present in several brain regions, but only hypophysiotropic 
TRH neurons located in the PVN are involved in the central regulation of the HPT axis (37).  
This nucleus is a critical vegetative center of the hypothalamus and located symmetrically at 
the upper third of the third ventricle. 
    The PVN contains a magnocellular and a parvocellular division.  The magnocellular 
division houses oxytocin and vasopressin neurons that project to the posterior pituitary.  The 
parvocellular division is further divided into anterior, periventricular, medial, ventral, dorsal 
and lateral parvocellular subdivisions (38).  In rats, TRH neurons are found in all 
parvocellular subdivisions (Fig. 2 A-C) (39), but the hypophysiotropic TRH neurons are 
located only in the medial and periventricular subdivisions at the mid and caudal levels of the 
PVN (Figs. 2 D-F, 3 A-F) (40-42).  In mice, hypophysiotropic TRH neurons are located only 
at the mid level of the PVN (Fig. 3 G-L), intermingled with the magnocellular neurons (43, 
44).  The periventricular subdivision of the PVN does not contain TRH neurons, and the 
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medial parvocellular subdivision at the caudal levels of the PVN houses non-
hypophysiotropic TRH neurons (43, 44).  In humans, the PVN also contains a large 
population of TRH neurons especially in its medial part, but the location of hypophysiotropic 
TRH neurons is not yet known (45, 46).  
    Hypophysiotropic TRH neurons are functionally different from the non-hypophysiotropic 
TRH neurons in the PVN.  Only hypophysiotropic TRH neurons project to the external zone 
of the median eminence (Fig. 4) where their axon terminals release TRH into the extracellular 
space of this blood-brain barrier-free circumventricular organ (37).  TRH is then conveyed to 
the anterior pituitary via the hypophysial portal circulation where TRH regulates the secretion 
of TSH from thyrotrophs and prolactin from lactotrophs (37, 47).  In addition to TRH, 
hypophysiotropic neurons also express a second neuropeptide, cocaine- and amphetamine 
regulated transcript (CART) (42, 48).  CART is simultaneously released into the hypophysial 
portal circulation and has been shown to inhibit the effect of TRH on prolactin secretion, but 
has no effect on TRH-induced release of TSH (49).  Hypophysiotropic TRH neurons also 
express the vesicular glutamate transporter 2 (VGLUT2), establishing the glutamatergic 
phenotype of these cells (50).  Since TRH axon terminals in the median eminence contain a 
large number of small, clear vesicles (51), it is likely that glutamate is co-released with TRH, 
but its physiological significance in the median eminence is currently unknown.  
    In contrast to the hypophysiotropic TRH neurons, non-hypophysiotropic TRH synthesizing 
neurons are widely distributed in the central nervous system (39).  Currently relatively little 
information is known about the projection fields and function of these neuronal groups, but 
some may be involved in the regulation of energy homeostasis.  Non-hypophysiotropic TRH 
neurons in the anterior parvocellular subdivision of the PVN, for example, are densely 
innervated by inputs containing feeding-related peptides including axons containing AGRP, 
α-MSH, CART, galanin and GALP (42, 52, 53).  In addition, these cells project to feeding-
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related nuclei such as the arcuate and dorsomedial nuclei and the amygdala (54).  In the 
perifornical region, TRH is co-synthesized with another anorexigenic peptide, urocortin 3 
(UCN3) (55).  These neurons have a prominent projection field to the hypothalamic 
ventromedial nucleus (54, 55), known to be involved in the regulation of food intake (56).  
TRH neurons in the preoptic area influence energy homeostasis by regulating thermogenesis 
(57). 
 
f. Neuronal inputs of hypophysiotropic TRH neurons 
    Hypophysiotropic TRH neurons are embedded in a dense network of neuronal axons in the 
PVN.  These axons form numerous synaptic associations on the surface of TRH neurons and 
modulate the activity of these cells (58).  Integration of these inputs together with humoral 
signals that can reach TRH neurons through the rich vascular supply of the median eminence 
or the PVN (59, 60), ensures fine tuning of the activity of the HPT axis and its adaptation to 
changing environmental conditions.  Currently, three, main, neuronal groups are known to 
send synaptic inputs to the hypophysiotropic TRH neurons: the hypothalamic arcuate nucleus, 
the hypothalamic dorsomedial nucleus (DMN), and catecholamine-producing neurons in the 
brainstem (Fig. 5, 6) (58, 61). 
    The hypothalamic arcuate nucleus plays key role in the regulation of energy homeostasis by 
relaying humoral signals to second order neuronal groups in the brain (56).  Two, major, 
feeding-related neuronal populations are involved, the medially-located, orexigenic neurons 
that synthesize neuropeptide Y (NPY), agouti related protein (AGRP) and gamma-amino 
butyric acid (GABA), and laterally located anorexigenic neurons that produce alpha-
melanocyte-stimulating hormone (α-MSH) and CART (56).  Both neuronal groups are 
responsive to peripheral, feeding-related signals such as changes in leptin, ghrelin, insulin and 
glucose (56), but are oppositely regulated (56). 
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    Numerous AGRP- and NPY-immunoreactive (IR) axon varicosities form juxtaposition with 
virtually all TRH neurons in the PVN (Fig. 5 A) and establish a symmetric type of synaptic 
association with these cells, indicative of an inhibitory function (52, 62, 63).  Since the 
neurons that synthesize AGRP are found only in the arcuate nucleus, the innervation of the 
TRH neurons by AGRP-IR axons must originate exclusively from this nucleus (63).  NPY, 
however, is synthesized by a number of neuronal populations, but the two major sources for 
the NPY-IR innervation of the PVN are the arcuate nucleus and catecholaminergic neurons in 
the brainstem (64).  The arcuate nucleus neurons provide approximately 75% of the NPY 
innervation to TRH neurons in the PVN (64, 65), while the adrenergic NPY neurons of the 
brainstem contribute the remaining 25% (64). 
    Anorexigenic α-MSH/CART neurons of the arcuate nucleus also innervate TRH neurons in 
the PVN (Fig. 5 A) (58), but establish fewer synapses than observed for axons containing 
AGRP/NPY (52).  α-MSH is synthesized in two brain regions, the hypothalamic arcuate 
nucleus and the nucleus tractus solitarius (NTS) of the brainstem.  Only α-MSH-containing 
neurons in the arcuate nucleus co-express CART (42), and therefore, the co-localization of 
these two peptides can be used as a marker for α-MSH axons originating from the arcuate 
nucleus.  As all α-MSH-IR axon varicosities on the surface of the TRH neurons contain 
CART, the arcuate nucleus is the exclusive source of the α-MSH-IR innervation to TRH 
neurons in the PVN (42).  Not all CART-IR axons in juxtaposition to the TRH neurons 
contain α-MSH, however, indicating that the arcuate nucleus is not the only source for the 
CART-IR innervation of these cells (42).  Indeed, only a relatively small portion of the 
CART-IR varicosities on the surface of TRH neurons derive from the arcuate nucleus.  
CART-synthesizing neurons that innervate the PVN can also be found in the lateral 
hypothalamus, perifornical area, zona incerta, C1-3 adrenergic neuronal groups and the 
medial subnucleus of the NTS (66).  As unilateral transection of the ascending brainstem 
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pathways to the PVN results in an approximately 60% reduction of the CART innervation of 
hypophysiotropic TRH neurons, it would appear that the brainstem gives rise the majority of 
the CART input to these cells (67).  
    TRH neurons in the PVN of the human hypothalamus also receive inputs from the 
infundibular nucleus, the analogue of the rodent arcuate nucleus (46).  Similar to the rodent, 
the human infundibular nucleus contains separate populations of AGRP/NPY and α-MSH-
synthesizing neurons (46).  In addition, TRH neurons in the human PVN are densely 
innervated by axons containing these peptides (46), suggesting that the arcuato (infundibulo)- 
paraventricular pathway is evolutionarily conserved and thereby, of importance in the 
regulation of hypophysiotropic TRH neurons (46).  There is a major difference between the 
human and the rodent pathways, however.  While CART and α-MSH are co-expressed by the 
arcuate nucleus neurons in the rodent, CART is not present in α-MSH neurons of the human 
infundibulum (68).  Moreover, CART can be detected in approximately 30% of AGRP/NPY 
neurons (68), indicating that CART may have a somewhat different role in the regulation of 
the thyroid axis in humans.  
    The DMN also plays important role in the regulation of energy homeostasis and vegetative 
functions (69).  Like the feeding-related neurons of the arcuate nucleus, DMN neurons sense 
circulating energy homeostasis-related hormones such as leptin (70), but these signals also 
influence the DMN indirectly via the arcuate nucleus (71).  In addition, the DMN is a critical 
node in the circuit regulating food-entrainable circadian rhythms and the stress response (69, 
72), integrating these signals and relaying the information to other neuronal populations such 
as the sympathetic nervous system and the PVN (69).  The DMN also contributes to the 
regulation of the hypothalamic-pituitary-thyroid axis, as bilateral destruction of the DMN 
increases 24h release of T3 (73), suggesting a net inhibitory effect.  Indeed, anterograde tract 
tracing studies have demonstrated (Fig. 5 B) that the vast majority of the TRH neurons in the 
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PVN receive input from the DMN, primarily establishing symmetric type synaptic 
associations with the TRH neurons characteristic of an inhibitory function (74).  Little is 
known about how the DMN regulates hypophysiotropic TRH neurons, however, but it has 
been hypothesized that it may be involved in circadian regulation of the hypophysiotropic 
TRH neurons (58). 
    Brainstem catecholaminergic cells groups are involved in the regulation of a wide variety 
of physiological functions including attention, sleep ⁄ wakefulness, learning, memory, 
emotion, reproduction, neuroendocrine processes and central responses to stress (75).  These 
neurons can be subdivided into adrenergic and noradrenergic subtypes based on their 
transmitter content.  Both neuronal populations produce dopamine-beta hydroxylase (DBH), 
the noradrenaline-synthesizing enzyme, but only adrenergic neurons express 
phenylethanolamine N-methyltransferase (PNMT), the enzyme that converts noradrenaline to 
adrenaline (76).  
    Hypophysiotropic TRH neurons receive a dense catecholaminergic innervation (77), 
perhaps comprising the largest input to these neurons.  Catecholaminergic axons establish 
asymmetric type synaptic specializations on the surface of TRH neurons (77), indicative of an 
activating effect and consistent with the observation that noradrenaline stimulates the 
transcription of TRH gene (78).  It has been shown by triple-labeling immunofluorescence 
(Fig. 5 C) that approximately two thirds of the catecholaminergic innervation of TRH neurons 
originate from adrenergic neurons, while the noradrenergic neuronal groups give rise to the 
remaining one third (61).  Adrenergic neurons are located exclusively in the C1-3 regions of 
the medulla, and since the axons of all three adrenergic regions have highly similar 
distribution patterns in the PVN (79), it is likely that each adrenergic group contributes to the 
innervation of hypophysiotropic TRH neurons (61).  
16 
 
    In addition to the classical transmitters, subpopulations of the adrenergic neurons that 
innervate the TRH neurons in the PVN also synthesize peptidergic transmitters. 
Approximately, 50% of the adrenergic innervation to TRH neurons co-contain CART (80), 
and more than 70% co-contain NPY (64).  A large proportion of these adrenergic terminals 
contain pituitary adenylate cyclase-activating polypeptide (PACAP) (81).  Currently, it is 
unknown how the co-release of multiple transmitters modulates the effect of adrenergic 
neurons on their targets, but it is likely that the capacity to release a large array of transmitters 
from the same terminals provides substantial flexibility for the ability of adrenergic neurons to 
differentially respond to diverse physiological and pathophysiological conditions. 
    The brainstem has six noradrenergic cells groups (A1-6), but only the A1, A2 and A6 
noradrenergic cell groups project to the PVN (82).  The A1 noradrenergic cell group 
innervates primarily the magnocellular part of the PVN in rats (83), suggesting that this cell 
group may be only a minor source of the noradrenergic innervation to TRH neurons.  The A2 
and A6 noradrenergic cells groups, however, densely innervate the periventricular and medial 
parvocellular subdivisions of the PVN where the hypophysiotropic TRH neurons reside (83), 
making it likely that these two noradrenergic cell populations are the primary sources of the 
innervation of hypophysiotropic TRH neurons. 
    In addition to the above mentioned inputs, the TRH neurons in the PVN receive galanin-, 
TRH-, corticotrophin-releasing hormone (CRH)-, somatostatin- and endocannabinoid 
receptor-containing inputs (50, 53, 81, 84-87).  Non-synaptic contacts between serotoninergic 
axons and the TRH neurons have also been described (88).  However, very little is known 
about the involvement of these inputs in the regulation of hypophysiotropic TRH neurons.  
The known inputs of the hypophysiotropic TRH neurons are summarized in Figure 6. 
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g. Tanycytes as regulators of the hypothalamic-pituitary-thyroid axis 
    Tanycytes are specialized glial cells lining the ventrolateral walls and the floor of the third 
ventricle between the rostral and caudal limits of the median eminence (Fig. 7 A, B) (89).  
Characteristic of these cells are a small cell body located in the ependymal layer, and a long, 
basal process that projects either into to the median eminence or the arcuate, ventromedial or 
dorsomedial nuclei (90).  Based on their location, morphology, cytochemistry and 
ultrastructure, tanycytes can be classified into four subtypes, 1 and 2 tanycytes that line the 
ventrolateral walls of the third ventricle, and β1 and β2 tanycytes that line the floor and lateral 
extensions of the third ventricle (Fig. 7 B) (89, 90).  Alpha 1 tanycytes are located 
approximately in the middle third of the ventricular wall and project into the ventromedial and 
dorsomedial nuclei where their end feet processes terminate on neurons (89, 90).  Alpha 2 
tanycytes are located ventral to α1 tanycytes and project their processes into the arcuate 
nucleus, terminating on neurons and around capillaries.  The most ventrally located α2 
tanycytes, however, send their processes to the most lateral portion of the tuberoinfundibular 
sulcus (89, 90). 
    Beta 1 tanycytes line the lateral invaginations of the infundibular recess, and their processes 
arch toward the tuberoinfundibular sulcus and terminate on the surface of the pars tuberalis of 
the pituitary (89, 90). The β2 tanycytes line the floor of the infundibular recess, and their 
processes travel through the median eminence to terminate around the portal capillaries in the 
external zone of the median eminence (89, 90).  
    In addition to their distinct anatomical locations, the various tanycyte subtypes also differ 
in their chemical signatures, suggesting that they have independent functions.  Alpha and β1 
tanycytes express the glucose transporter-1, a blood-brain barrier (BBB) marker (91).  This 
observation is in keeping with the morphological observations that α tanycytes surround 
capillaries in the arcuate and ventromedial nuclei and β1 tanycytes create the barrier that 
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separates median eminence from the mediobasal hypothalamus (91).  However,  but not  
tanycytes express somatostatin sst2a receptors, whereas β1 tanycytes are reactive for N-
cadherin, while only α1 tanycytes express adenosine triphosphatase enzyme (90).  In addition, 
β2 tanycytes lack the glucose transporter-1 but express Rab 4, a protein involved in vesicular 
transport (90, 91). 
    At the ultrastructural level, a common characteristic of tanycytes is the presence of both 
early and late endosomes near the apical surface of the cell bodies, suggesting that all types of 
tanycytes actively incorporate substances from the CSF (90).  However, as tight junctions are 
absent between α and β1 tanycytes (90), substances from the CSF can also enter the neuropil 
directly through the ventrolateral portions of the third ventricular wall.  In contrast, β2 
tanycytes are bound together by both zonula adherens and tight junctions, forming an 
impermeable barrier between the CSF and the median eminence (90).   
    In addition to functioning as barrier cells, it is becoming increasingly clear that tanycytes 
are involved in neuroendocrine regulation (90).  The role of tanycytes in the regulation of the 
hypothalamic-pituitary-gonadal axis has been long known (90).  Changes in estrogen levels 
induce cytoskeletal remodeling of tanycytes resulting in retraction of tanycyte end processes 
from the capillaries during the GnRH surge, allowing GnRH axons to secrete their products 
into the portal circulation (92).  The role of tanycytes in the regulation of the HPT axis has 
been more recently recognized (89).  Tanycytes express thyroid hormone receptors (Fig. 7 C, 
D), and changes in circulating thyroid hormone levels result in plastic remodeling of tanycyte 
end feet processes (28, 93), perhaps also to regulate the entry of TRH released by the 
hypophysiotropic terminals into the portal circulation (93).  In addition, the tanycytes express 
the TRH degrading enzyme, pyroglutamyl peptidase II (PPII, Fig. 7 H) (35), which is 
regulated in parallel to circulating thyroid hormone levels (35).  Thus, hyperthyroidism results 
in upregulation of tanycyte PPII, contributing to inhibition of TSH secretion by reducing the 
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amount of TRH reaching the portal system.  In support of this hypothesis, inhibition of PPII in 
the median eminence of hyperthyroid animals significantly increases the amount of secreted 
TRH (35). 
    Tanycytes are also thought to be involved in feedback regulation of the HPT axis through 
their expression of type 2 iodothyronine deiodinase (D2, Fig. 7 E-G), an enzyme that 
catalyzes 5’ deiodination of T4 resulting in the generation of the active form of thyroid 
hormone, triiodothyronine (T3) (94).  In most regions of the brain, D2 is expressed by 
astrocytes, but in the hypothalamus, D2 is primarily expressed by tanycytes (95-97).  Most 
regions of the hypothalamus including the PVN are devoid of D2 activity (98). 
    Tanycyte D2 activity is precisely regulated at transcriptional and posttranslational levels 
(58, 99).  Tanycytes synthesize ubiquitine ligase and deubiquitinase enzymes, WSB1 and 
USP33, respectively, that can quickly and reversibly regulate the activity of D2 (100).  In 
addition, tanycytes are richly replete in the thyroid hormone transporters, MCT8 and 
OATP1C1 (Fig. 7 C, D) (51, 101, 102), that facilitate the entry of T4 from the circulation or 
CSF, and release generated T3 into the neuropil or CSF.  Under special conditions, tanycytes 
also express the thyroid hormone degrading enzyme, type 3 iododthyronine deiodinase 
enzyme (D3) (103).  Precise transcriptional and posttranslational regulation of D2 and D3 in 
tanycytes provides for a powerful mechanism to tightly control hypothalamic T3 availability 
that may contribute to regulation of the HPT axis. 
 
h. Involvement of the autonomic nervous system in the regulation of the hypothalamic-
pituitary-thyroid axis 
    In addition to the stimulation of TSH secretion of the anterior pituitary by TRH, the central 
nervous system can also regulate thyroid function via the autonomic nervous system.  The 
thyroid gland is innervated by both adrenergic nerve fibers of the sympathetic nervous system 
and the cholinergic axons originating from the vagus nerve (104, 105).  Both sympathetic and 
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parasympathetic nerves densely innervate the blood vessels of the thyroid gland, but axon 
terminals of these autonomic systems can also be found around the thyroid follicles (104, 
105), indicating that not only the blood flow, but also the activity of thyroid follicles could be 
under direct control of autonomic inputs.  Retrograde, virus mediated tract tracing studies has 
verified the existence of both the sympathetic and parasympathetic innervation of the thyroid 
gland, showing that two days after the injection of pseudorabies virus directly into the thyroid 
gland,  sympathetic preautonomic neurons in the intermediolateral column of the spinal cord 
and the parasympathetic preautonomic neurons in the dorsal vagal complex were retrogradely 
labeled (106).  
….Relatively little data is available about how the autonomic inputs to the thyroid gland 
regulate thyroid function.  However, the sympathetic input seems to have an inhibitory action 
as electrical stimulation of the cervical sympathetic trunk decreases thyroid blood flow (107).  
Noradrenaline also inhibits the stimulatory effect of TSH on the thyroid cells in vitro (108) 
and decreases thyroid hormone secretion in vivo (109). 
In contrast, electric stimulation of thyroid nerve, that carries parasympathetic inputs to the 
thyroid gland, results in increased thyroid blood flow that can be prevented by atropine pre-
treatment (107).  In addition, transection of inferior laryngeal nerve that also carries 
parasympathetic input to the thyroid gland results in a fall of circulating T4 levels, supporting 
the stimulatory effect of the parasympathetic inputs on the activity of thyroid gland (110). 
    In addition to the classical transmitters, the neuropeptides, NPY and vasoactive intestinal 
peptide (VIP), are also present in axons innervating the thyroid gland (107).  NPY is present 
in the sympathetic innervation of the thyroid gland and similar to norepinephrine, inhibits 
thyroidal blood flow (111).  In contrast, VIP increases the thyroid blood flow and thyroid 
hormone secretion (107). 
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    In addition to the primary preautonomic neuronal groups, multisynaptic connection of the  
the suprachiasmatic nucleus and energy homeostasis related neuronal groups of the 
hypothalamus including the PVN and the arcuate nucleus with the thyroid gland have also 
been demonstrated (106), suggesting that these hypothalamic cell groups may also be 
involved in the autonomic regulation of thyroid gland.  As cenral melanocortin and NPY 
signaling contributes to the metabolism of thyroid hormone in the liver by regulating 
sulfotransferases (112), it is conceivable that the autonomic nervous system is also involved 
in regulating the peripheral metabolism of thyroid hormones in addition to their synthesis, 
although the mechanism remains uncertain. 
 
III. Negative feedback regulation of hypophysiotropic TRH neurons 
a. Classical view of negative feedback regulation 
    Negative feedback regulation of hypophysiotropic TRH neurons is an important regulatory 
mechanism to ensure stability of circulating thyroid hormone levels (113).  When circulating 
thyroid hormone levels are increased, TRH gene expression is decreased in hypophysiotropic 
neurons, whereas the converse is true in association with hypothyroidism (Fig. 8) (58).  
Regulation of TRH transcription by thyroid hormone is relatively rapid, as the exogenous 
administration of thyroid hormone can suppress transcription of the TRH gene in the PVN 
within 5 h (114).  This regulatory mechanism is a unique feature of hypophysiotropic TRH 
neurons, as thyroid hormone does not regulate TRH gene expression in non-hypophysiotropic 
TRH neurons (113).  Thyroid hormone is sensed directly by the hypophysiotropic TRH 
neurons since implantation of crystalline T3 immediately adjacent to the PVN in hypothyroid 
animals results in marked inhibition of TRH mRNA on that side, but has no effect on TRH 
neurons on the contralateral side (115). 
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    Hypophysiotropic TRH neurons express the TRα1, TRβ1 and TRβ2 isoforms of the thyroid 
hormone receptors, although the TRβ1 isoform is present in relatively low abundance (116).  
The presence of all three thyroid hormone receptor isoforms in the same cell type may seem 
to be redundant.  However, all isoforms have different roles in the regulation TRH gene 
expression in the hypophysiotropic neurons.  In TRβ knock out mice, in which TRα1 is the 
only functional thyroid hormone receptor, T3 treatment results in a significant increase of 
TRH gene expression in the PVN, while the lack of TRα1 in TRα knock out mice enhances 
the T3-induced decrease in TRH mRNA in the PVN (117).  These data suggest that T3 
positively regulates the TRH gene via TR1.  This view is also supported by the stimulatory 
effect of T3 on the TRH gene expression in cell cultures of developing hypothalamic cells at 
the 12 DIV stage when the TRα1 is the predominant TR isoform (118).  This TRα1 mediated 
stimulatory effect of T3 can be overridden by the TRβ-mediated inhibitory effect of T3 in 
wild type mice and also in later stages of cultured hypothalamic cells (117, 118).  Since a 
positive TRE has not been identified in the promoter of TRH gene, it is not clear whether the 
TRα1-mediated stimulatory effect exerted directly on the TRH promoter or through indirect 
effects (118).  In contrast to the TRα knock out mice, the T3 induced inhibition of TRH gene 
expression is completely absent in the PVN of both TRβ and TRβ2 knock out mice (117, 
119).  Therefore, it has been suggested that negative feedback regulation of the TRH gene is 
mediated exclusively by the TRβ2 isoform (119).  This view was challenged by Guissouma et 
al. (120) using siRNA-mediated knock down of the different TRβ isoforms in the 
hypothalamus of mouse pups.  The results of these experiments revealed that siRNA-mediated  
knock down of either TRβ2 or TRβ1 prevents the T3 dependent inhibition of the activity of a 
TRH-luciferase construct transfected into the hypothalamus, suggesting that both TRβ1 and 
TRβ2 contribute to negative feedback regulation of the TRH gene.  It is not clear, however, 
how the two TRβ isoforms interact in this regulatory process. 
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    The two TRβ isoforms, however, unequivocally play different roles in ligand-independent 
stimulation of the TRH gene (117, 120).  While the TRH mRNA level is markedly increased 
in the PVN of TRβ2 knock out mice independent of thyroid status (119), TRH expression is 
significantly decreased in both hypo- and euthyroid TRβ knock out mice (117).  These data 
suggest that the TRβ1 isoform is critical for ligand-independent stimulation of the TRH 
promoter and supported by evidence that siRNA-mediated knock down of the TRβ1 isoform 
significantly decreases activity of the TRH promoter in the mouse hypothalamus (120). 
    In addition to the regulation of TRH at the transcriptional level, thyroid hormone also 
influences posttranslational processing of proTRH.  Increased levels of circulating thyroid 
hormone lead to the downregulation of two, major, proTRH processing enzymes, PC1/3 and 
PC2, but selective to the PVN, resulting in the accumulation of intermediate processing 
products (121).  Thyroid hormone may also affect expression of neuropeptide receptors in 
hypophysiotropic TRH neurons, such as the melanocortin 4 receptor (122), influencing the 
sensitivity of TRH neurons to their excitatory and inhibitory inputs. 
 
b. Involvment of type 2 and type 3 deiodinases, thyroid hormone transporters and 
pyroglutamyl-peptidase II in negative feedback regulation of hypophysiotropic TRH 
neurons 
1.  Role of deiodinases 
    The concept that the circulating level of T3 is solely responsible for negative feedback 
regulation of hypophysiotropic TRH by acting directly on these neurons was challenged by 
Kakucska et al. (123), showing that restoration of circulating levels of T3 to normal in 
hypothyroid rats without the administration of T4 does not normalize TRH gene expression in 
the PVN (Fig. 9).  Only if very high, hyperthyroid levels of T3 were achieved in the 
circulating blood was it possible to decrease TRH mRNA levels in the PVN into the normal, 
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euthyroid range (123).  These data indicate that in addition to T3, circulating T4 is also 
necessary for appropriate feedback control of hypohysiotropic TRH neurons.  However, since 
T4 functions primarily as a prohormone, its conversion to T3 within the CNS must be an 
essential part of the feedback regulatory mechanism. 
    As noted previously, the conversion of T4 to T3 in the brain is catalyzed by D2 (94), and in 
the hypothalamus, this enzyme is expressed primarily in tanycytes (95-98, 124).  Although D2 
is also present in less abundance in astrocytes in the median eminence and arcuate nucleus 
region (95), selective ablation of D2 from astrocytes in transgenic mice has no significant 
effect on feedback regulation of the hypophysiotropic TRH neurons (125), indicating that 
astrocytes have little or no role in the regulation of this response.  Presumably, therefore, 
tanycyte D2 is responsible for generating the additional T3 required to maintain normal 
homeostasis in the thyroid axis, although this has not yet been directly tested experimentally.  
Under certain conditions, the thyroid hormone inactivating enzyme, type 3 iodothyronine 
deiodinase (D3), is also present in tanycytes (126, 127).  It is unknown, however, whether this 
enzyme contributes to the regulation of hypothalamic T3 concentrations. 
    In most brain regions, the primary role of D2 is to maintain local T3 concentrations if 
circulating levels of T4 and T3 decline (128).  In the cortex, for example, hypothyroidism 
upregulates D2 activity to produce more T3, while hyperthyroidism downregulates D2 
activity (94).  Therefore, the local T3 concentration in the cortex is unchanged even if the 
circulating T4 concentrations vary over a relatively wide range (128).  D2 is also regulated by 
thyroid hormone in tanycytes at the transcriptional level (97, 129), however, the increased 
gene expression is not accompanied by a rise of D2 activity in these cells (130).  While 
hypothyroidism results in a more than 4-fold increase of D2 activity in the cortex (131), it has 
no effect on D2 activity in the mediobasal hypothalamus (130).  Similarly, no increase in D2 
activity has been observed in the mediobasal hypothalamus in association with iodine 
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deficiency, contrary to other regions in the brain (132).  The posttranscriptional attenuation of 
thyroid hormone-induced regulation of D2 activity in the MBH suggests that the main role of 
D2 in this region is not to maintain a constant, local, T3 concentration, but rather to allow the 
hypothalamus to sense changes in peripheral thyroid hormone levels using T3 as a regulatory 
signal.  This feature is important because stable hypothalamic T3 concentrations would reduce 
the sensitivity of feedback regulation mechanism of TRH neurons in the PVN.  
    Despite all the above mentioned data supporting the role of D2 expression of tanycytes in 
the feedback regulation of the hypophysiotropic TRH neurons, D2 KO mice are euthyroid and 
their HPT axis has seemingly intact negative feedback regulation (133).  This data could 
question the role of D2 in the feedback regulation of the HPT axis.  However, it is important 
to note that during the embryonic period, thyroid hormone levels have a major influence on 
the development of the setpoint for feedback regulation of thyroid hormone on the HPT axis 
(134). In D2 KO animals, D2 activity is already absent from the tanycytes during the 
embryonic period.  Therefore, it is likely that during development, compensatory mechanisms 
are brought into play that allow feedback regulation of the HPT axis to proceed normally, 
even in the absence of the thyroid hormone activating capacity of tanycytes.  This hypothesis 
is supported by the observation that thyroid hormone availability during the neonatal period 
can highly influence the setpoint for negative feedback regulation of the HPT axis (135).  
Namely, exogenous administration of T4 during the first 12 days after birth results in a 
permanent decrease in circulating TSH and thyroid hormone concentrations that persists into 
adulthood despite the normal TSH secretory capacity of animals in response to exogenous 
TRH administration (135).  Were the setpoint of negative feedback regulation to be altered 
(lowered) during development by chronically low T3 levels in hypothalamus of D2 KO mice, 
the HPT axis of the adult D2 KO mice would be expected to function normally despite low T3 
availability in the hypothalamus of adult D2 KO mice.  However, it is likely that ablation of 
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D2 expression in adult animals would have far more profound impact on the parameters of the 
HPT axis.  
    Some hypophysiotropic axon terminals in the median eminence contain D3 (51), indicating 
that these neurons can regulate T3 availability intracellularly independent of the thyroid 
hormone concentration in the neuropil by degrading T3.  Importantly, however, the vast 
majority of the TRH-containing hypophysiotropic terminals do not contain D3 and therefore, 
do not have an internal mechanism for degrading T3 once taken up into the neuron (51).  
 
2.  Role of thyroid hormone transporters 
    Despite their lipophylic nature, the transport of thyroid hormone through cell membranes 
requires active transport (136).  Currently, two, main, thyroid hormone transporters are known 
to be involved in thyroid hormone transport in the brain, OATP1C1 and MCT8, members of 
the organic anion transporting polypeptide (OATP) and the monocarboxylate transporter 
(MCT) families, respectively (136).  OATP1C1 has a similar high affinity for T4 and T3 and 
is abundantly expressed in endothelial cells of brain blood vessels, the choroid plexus and 
tanycytes (102, 137).  The activity of the HPT axis is not affected by the lack of OATP1C1 in 
knockout mice (138), however, suggesting that this transporter does not play a crucial role in 
feedback regulation of TRH neurons.  In contrast, the MCT8 transporter, which is 
preferentially expressed in neurons including hypophysiotropic TRH neurons (51, 139), and 
tanycytes (139), has preferential affinity for T3 (139).  In MCT8 knockout mice, TRH gene 
expression increases in the PVN (140).   
    The location of tanycytes at the blood-brain and CSF-brain barriers, and their high 
expression of thyroid hormone transporters, place them in a strategic position to extract T4 
from the bloodstream or CSF.  The former could be accomplished through their end feet 
processes terminating on portal capillaries or on blood vessels in the arcuate nucleus, and the 
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latter via apical specializations after T4 has traversed the choroid plexus (101, 102, 141).  
While increased circulating levels of T3 in MCT8 KO mice, and the high expression of this 
transporter in tanycytes implicate MCT8 as an essential component of the  feedback 
regulation mechanism on hypophysiotropic TRH neurons, the considerable distance between 
tanycytes and the cell bodies of hypophysiotropic TRH neurons in the PVN raises questions 
as to how locally synthesized T3 can be transported from tanycytes to the perikarya of TRH 
neurons.  It was initially hypothesized that T3 released from tanycytes into the CSF or 
neuropil can reach TRH neurons by diffusion through the brain extracellular space (97).  This 
hypothesis, however, does not address how it is possible that only hypophysiotropic TRH 
neurons are regulated by the changes of peripheral thyroid hormone levels, whereas non-
hypophysiotropic TRH neurons in the hypothalamus (including the PVN) that also express 
thyroid hormone receptors, are not affected (116).  
    Despite the relatively large distance between the tanycytes and the perikarya of the 
hypophysiotropic TRH neurons, there is one location where the two cell types are closely 
associated.  This is the external zone of the median eminence where the axon terminals of 
hypophysiotropic TRH neurons are intertwined with end-feet processes of β2 tanycytes (142).  
MCT8 is present on the surface of practically all axon terminals in the external zone of the 
median eminence, including the terminals of hypophysiotropic TRH neurons (51).  This 
observation makes it likely that T3 secreted from the tanycytes can be taken up by 
hypophysiotropic TRH terminals via MCT8 and then transported to the perikarya of TRH 
neurons by retrograde, axonal transport.  In support of this hypothesis, early studies by 
Dratman et al. (143) presumed axonal transport of T3, based on the presence of radiolabeled 
T3 in neuronal processes and migration of autoradiographic signal among brain areas during 
the first 48h after iv administration of radiolabeled T3.  In addition, rapid retrograde axonal 
transport of other bioactive molecules such as neurotrophins, has already been proven (144, 
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145).  To demonstrate that retrograde transport of T3 from the median eminence actually 
occurs, and changes of peripheral thyroid hormone levels results in different intranuclear T3 
concentration in the hypophysiotropic and non-hypophysiotropic TRH neurons, however, will 
require further study. 
   The median eminence is a unique brain region, as its T3 content derives from at least two, 
different sources.  Being outside the blood brain barrier (90), T3 circulating in the peripheral 
blood can readily enter the extracellular space of the median eminence through fenestrated 
portal capillaries without the need for a specific transport mechanism.  However, tanycytes 
may also contribute to the T3 content in the median eminence given their high concentration 
of D2 (90) and hence, ability to convert T4 to T3.  As nearly a twice normal circulating level 
of T3 is required to normalize the TRH mRNA level in the PVN if only T3 is administered to 
rats after inhibition of thyroid hormone synthesis (123), the contribution of T3 derived from 
tanycytes may contribute substantially to the T3 content of the median eminence in euthyroid 
animals.  Since only hypophyiotropic TRH neurons project to the median eminence, this 
hypothesis would also provide an explanation for why hypophysiotropic and non-
hypophysiotropic TRH neurons are differentially regulated by thyroid hormone.  However, 
further studies are needed to demonstrate that the T3 content of hypophysiotropic and non-
hypophysiotropic TRH neurons is differentially regulated by changes of peripheral thyroid 
hormone levels. 
 
3.  Role of PPII 
    In addition to modulating feedback regulation of TRH neurons by influencing T3 
availability in the median eminence, tanycytes can also influence of the amount of TRH that 
reaches portal capillaries in the median eminence.  Tanycytes synthesize the TRH degrading 
enzyme, PPII, which is highly regulated by circulating levels of thyroid hormone (35).  
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Peripheral administration of T4 markedly increases PPII mRNA synthesis and activity in 
tanycytes (35).  Tanycyte end-feet processes surround the hypophysiotropic terminals in the 
external zone of the media eminence and PPII is a membrane bound protein with a large 
extracellular C-terminal region that contains the exopeptidase and catalytic motifs (146).  
Therefore, PPII synthesized by tanycytes is in anatomical position to degrade secreted TRH 
from TRH-containing axon terminals in the extracellular space of the median eminence (35).  
In support of this hypothesis, inhibition of PPII by Hermodice carunculata protease inhibitor 
(HcPI) increases TRH release from median eminence explants, whereas in vivo, a single 
peripheral injection of HcPI results in a significant increase in circulating TSH levels in 
animals exposed to a cold environment compared to the vehicle injected animals (35). 
    A summary of the mechanisms contributing to feedback regulation of hypophysiotropic 
TRH neurons is illustrated in Figure 10. 
 
IV. Central regulation of the hypothalamic-pituitary-thyroid axis during fasting 
    The HPT axis plays critical role in the regulation of energy expenditure by affecting basal 
metabolic rate and through the actions of thyroid hormone to stimulate mitochondrial oxygen 
consumption and increase thermogenesis (147).  It is not surprising, therefore, that 
alternations in energy availability would be intimately linked to control of the HPT axis.  
During fasting, for example, circulating thyroid hormone levels decline associated with low or 
normal TSH levels and inhibition of TRH gene expression in the PVN characteristic of central 
hypothyroidism (Fig. 11 A, B) (148-150).  Presumably, fasting-induced hypothyroidism is a 
homeostatic mechanism to conserve energy stores until food is once again available.  The 
mechanism by which hypophysiotropic TRH neurons sense alterations in peripheral energy 
stores is orchestrated by leptin, a white adipose tissue-derived circulating hormone, (148-
150), as fasting-induced central hypothyroidism can be completely prevented by the 
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exogenous administration of leptin (Fig. 11 C) (148).  The primary target site for leptin that 
mediates its effect on the HPT axis is the arcuate nucleus, because ablation of this nucleus 
abolishes both fasting- and leptin-induced regulation of the HPT axis (151).  The circuitry and 
peptide mediators involved are discussed in detail below and illustrated in Figure 12. 
 
a. Role of the arcuato-paraventricular pathway in the regulation of the HPT axis during 
fasting 
    Two antagonistic, neuronal populations in the arcuate nucleus, the orexigenic 
NPY/AGRP/GABA neurons and the anorexigenic α-MSH/CART neurons, are primarily 
responsible for sensing and relaying information to hypophysiotropic TRH neurons about the 
concentration of leptin in the bloodstream (56).  Both leptin-sensitive neuronal groups directly 
target hypophysiotropic TRH neurons and establish synaptic specializations with their 
perikarya and dendrites in the PVN (58).  Similar to leptin, central administration of α-MSH 
or CART to fasted animals completely prevents fasting-induced inhibition of TRH gene 
expression in the PVN (Fig. 13) (42, 52), and can increase TRH release from hypothalamic 
explants (52, 152).  α-MSH has also been shown to depolarize TRH neurons in the PVN and 
increase their firing rate (153).  In contrast, central administration of NPY or AGRP to fed 
animals induces a state of central hypothyroidism similar to that observed in fasted animals 
(Fig. 14), despite that the animals markedly increase their food intake secondary to the potent 
orexigenic effect of NPY (152, 154, 155).  NPY has also been shown to hyperpolarize the 
TRH neurons in the PVN and decrease the firing rate of these neurons (153). 
    The α-MSH/CART and NPY/AGRP/GABA arcuate neurons interact at multiple levels to 
regulate hypophysiotropic TRH neurons.  First, both α-MSH and AGRP are ligands of the 
melanocortin 3 and 4 receptors (MC3R and MC4R) (156), with α-MSH functioning as an 
agonist and AGRP as a high affinity antagonist (156).  The MC4R is expressed by 
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hypophysiotropic TRH neurons (24), and as the inhibitory effect of AGRP on TRH gene 
expression is abolished in MC4R KO mice (157), melanocortin signaling to TRH neurons 
must be mediated primarily by the MC4R.  All TRH neurons that are innervated by α-MSH-
containing axon varicosities are also innervated by AGRP-containing terminals (Fig. 5 A) 
(52), indicating direct, functional interactions between these two peptides.  The interaction of 
the two peptides in the regulation of the TRH neurons is further supported by in vitro studies, 
demonstrating that AGRP prevents the stimulatory effect of α-MSH on TRH release (152).  
    A second mechanism may involve post-receptor effects arising from the interaction 
between -MSH and NPY.  The MC4R is coupled to Gs proteins and when activated by -
MSH, induces the adenylyl cyclase–protein kinase A cascade (158).  The resultant increase in 
cAMP and hence, CREB phosphorylation, regulates TRH gene expression by the binding of 
phosphoCREB (pCREB) to cAMP response elements (CREs) present in the TRH gene (21, 
159).  NPY also regulates cAMP synthesis, but as NPY receptors couple to Gi or G0 proteins, 
NPY inhibits adenylate cyclase, reducing cAMP accumulation (160).  In this manner, NPY 
could inhibit α-MSH-induced CREB phosphorylation in hypophysiotropic TRH neurons by 
reducing the intracellular cAMP concentration.  In fact, pretreating animals with centrally 
administered NPY markedly reduces the ability of icv injected -MSH to induce CREB 
phosphorylation in TRH neurons (161).  
    The inhibitory effects of NPY on hypophysiotropic TRH neurons are mediated primarily by 
Y1 and Y5 receptors, as the central administration of either selective Y1 or Y5 receptor 
agonists are equally effective in inhibiting hypophysiotropic TRH gene expression and the 
HPT axis (162).  In addition, Y1 receptor mRNA is expressed in TRH neurons in the PVN 
(163), and the Y5 receptor has been localized to the PVN (164), although its specific 
expression in hypophysiotropic TRH neurons has not been studied.  Since the fasting-induced 
fall of leptin stimulates NPY/AGRP neurons and inhibits α-MSH/CART neurons (56), the 
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increased inhibitory tone of orexigenic peptides and simultaneous decrease in the stimulatory 
input from anorexigenic neurons of arcuate nucleus origin play a critical role in the 
development of fasting-induced central hypothyroidism.  This hypothesis is supported by 
evidence showing that fasting-induced central hypothyroidism is prevented in mice lacking 
both NPY and the MC4R (112).  
    Currently, little is known about the interactions between CART and melanocortins or NPY, 
partly hindered by the fact that the CART receptor(s) has not yet been identified.  Central 
administration of CART increases CREB phosphorylation at least in the CRH neurons in the 
PVN, but pCREB is absent from hypophysiotropic TRH neurons after this treatment (165).  
Therefore, it is unknown whether the effect of CART on the hypophysiotropic TRH neurons 
involves the interaction with the NPY and AGRP signaling at the level of second messengers, 
or only at the level of the TRH promoter.   
    In addition to leptin, insulin and glucose also have anorexigenic effects when administered 
centrally (56).  Circulating levels of these substances decrease during fasting and are sensed 
by the feeding-related neurons of the arcuate nucleus (56), raising the possibility that similar 
to leptin, insulin and glucose are also involved in fasting-induced regulation of 
hypophysiotropic TRH neurons.  However, while central administration of leptin completely 
prevents fasting-induced inhibition of the TRH gene expression, central administration of 
insulin or glucose has no effect on TRH gene expression in fasted rats (166).  These 
observations suggest that changes in insulin and glucose levels do not have a critical role in 
the fasting-induced regulation of the HPT axis, and indicate that leptin, insulin and glucose 
have different effects on feeding-related neuronal groups in the arcuate nucleus.  Indeed, 
while leptin can completely reverse fasting-induced changes in NPY, AGRP, POMC and 
CART gene expression in arcuate nucleus neurons, centrally administered insulin only affects 
NPY and POMC gene expression, and glucose only affects NPY gene expression (166).  
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Therefore, it would appear that all four feeding-related peptides of arcuate nucleus origin are 
necessary to appropriately regulate hypophysiotropic TRH neurons during fasting through the 
arcuato-paraventricular pathway (166).  
    Similar to the rodent arcuate nucleus, the human infundibular nucleus also contains neurons 
that co-express AGRP and NPY, and neurons that synthesize -MSH (46).  These neuronal 
populations give rise to axonal projections that directly innervate TRH neurons in the PVN 
(46).  In contrast to the rodent, however, CART is not co-synthesized with -MSH, but is 
present in a subpopulation of the AGRP- and NPY-synthesizing neurons in the infundibular 
nucleus (68).  The significance of this difference is uncertain, but raises the possibility that 
CART may have a different role in the regulation of the HPT axis in the human brain 
compared to that observed in rodents (68). 
 
b. Direct action of leptin on hypophysiotropic TRH neurons 
    Despite the observation that regulation of the hypophysiotropic TRH neurons by fasting 
and leptin is lost in arcuate nucleus ablated animals (151), there has been an ongoing debate 
about whether leptin can exert a direct effect on hypophysiotropic TRH neurons (24, 37, 58, 
153, 167).  The presence of the leptin receptor in TRH neurons was shown in primary cultures 
of fetal rat hypothalamic cells (167), but the approach used did not differentiate between 
hypophysiotropic TRH neurons and the many other TRH-synthesizing neuronal populations 
present in the hypothalamus.  In addition, it is not clear whether the expression of the leptin 
receptor observed in fetal cultures is sustained in adult animals or only exists transiently 
during development.  Harris et al. (24), however, have convincingly demonstrated that leptin 
administration induces the expression of suppressor of cytokine signaling 3 (SOCS3), an 
accepted marker of leptin receptor signaling, in a small subset (10%) of TRH neurons in the 
PVN.  Furthermore, signal transducers and activators of transcription-3 (STAT3), a second 
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messenger utilized by the leptin receptor, was shown to directly bind to the TRH promoter in 
mouse hypothalamus after peripheral administration of leptin (24).  These data support the 
notion that a subgroup of hypophysiotropic TRH neurons in the PVN can be directly targeted 
by leptin, a view further supported by in vitro patch clamp electrophysiology data, 
demonstrating a direct excitatory effect of leptin on TRH neurons in the PVN (153).  
    However, it remains uncertain under what physiologic conditions direct vs indirect leptin 
signaling to TRH neurons is utilized physiologically.  During fasting, it seems clear that the 
arcuato-paraventricular pathway is most important pathway that mediates the effect of leptin 
on hypophysiotropic TRH neurons.  This is based on the observations that arcuate nucleus 
ablation prevents the effect of fasting and leptin administration on TRH gene expression in 
the PVN (148).  In addition, while central administration of leptin results in both STAT3 and 
CREB phosphorylation in TRH neurons of the PVN (168), the administration of the 
melanocortin antagonist, SHU9119, completely prevents the stimulatory effect of centrally 
administered leptin on TRH release and TSH secretion (168), indicating that leptin influences 
hypophysiotropic TRH neurons primarily via the melanocortin system.  Furthermore, in 
NPY/MC4R double KO mice lacking both NPY and melanocortin signaling, fasting-induced 
suppression of the HPT axis is completely prevented (112).  These data, however, do not 
exclude the possibility that a direct effect of leptin on hypophysiotropic TRH neurons may be 
of secondary importance by increasing the expression of MC4R in these neurons (169) and 
hence, their melanocortin sensitivity.  In this manner, a direct effect of leptin may sensitize 
hypophysiotropic TRH neurons to the arcuate nucleus inputs, rather than directly influence 
the activity in these cells.  A direct effect of leptin on hypophysiotropic TRH neurons, 
however, may be of importantance in maintaining the activity of the HPT axis in association 
with obesity (170), and is discussed in greater detail in section VI. 
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c. Involvement of tanycytes in the regulation of the HPT axis during fasting 
    In addition to neuronal groups projecting onto hypophysiotropic TRH neurons and a direct 
action of leptin, hypothalamic tanycytes may also participate in the central regulation of the 
HPT axis during fasting.  Fasting results in an approximately 2-fold increase in D2 
hybridization signal in the mediobasal hypothalamus (130) and a 1.6-fold increase of D2 
activity (130).  These changes are independent of the fasting-induced fall in peripheral thyroid 
hormone levels (130), as hypothyroidism has a relatively minimal effect on D2 activity in the 
MBH, and T4 treatment does not prevent the fasting-induced increase in MBH D2 activity 
(130).  Changes of leptin or corticosterone levels, alone, have no effect on D2 activity in the 
MBH of fed animals (171), but either removal of the adrenal glands or preventing leptin 
levels from falling during fasting prevents the increase in D2 activity in the MBH in fasting 
animals (171).  It is hypothesized, therefore, that the fall in leptin levels in fasted animals has 
a permissive role to enable the stimulatory effect of corticosterone on D2 activity (171).  It 
has been further suggested that the fasting-induced increase of D2 activity in the MBH may 
contribute to inhibition of the HPT axis by increasing local tissue levels of thyroid hormone 
(172).  This hypothesis is supported by a report that third ventricular administration of a 
deiodinase inhibitor, iopanic acid, prevents the fasting-induced increase in hypothalamic T3 
concentrations and blunts inhibition of TRH gene expression in the PVN (172).  However, 
iopanoic acid has broad target specificity, inhibiting all deiodinase enzymes and blocking 
thyroid hormone transporters (173, 174).  Therefore, it cannot be unequivocally stated that the 
observed effect of iopanoic acid treatment is due to inhibition of D2 activity in the MBH, 
especially because the fasting-induced fall in thyroid hormone levels is very similar in wild 
type and D2 KO mice (175).  An alternative hypothesis is that increased T3 production by 
tanycytes stimulates NPY neurons in the arcuate nucleus (175), indirectly inhibiting TRH 
neurons in the PVN.  However, since thyroid hormone has no inhibitory effect on 
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hypophysiotropic TRH neurons in TRβ2 KO mice, but the fasting-induced suppression of 
TRH mRNA in the PVN is completely intact in these animals (119), tanycyte generated T3 
during fasting likely has a minimal role in the regulation of the HPT axis.  In addition, fasting 
inhibits TRH neurons in the PVN of Siberian hamsters regardless of whether they are kept 
under short or long day photoperiods, even though fasting has opposite effects on tanycyte D2 
activity during long and short day photoperiods (176). 
 
d. Role of other neuronal pathways in the regulation of the HPT axis during fasting 
    In addition to the arcuate nucleus, TRH neurons also receive inputs from other neuronal 
groups known to be involved in the regulation of energy homeostasis including the 
hypothalamic dorsomedial nucleus and neuronal groups in the brainstem (58).  Axons arising 
from all subdivisions of the DMN densely innervate the vast majority of TRH neurons in the 
PVN, (74).  Approximately two thirds of the PVN projecting DMN neurons are located in the 
medial part of ventral subdivision of the DMN, however, with neurons in the compact 
subdivision contributing only approximately 10% (71). 
    The physiologic importance of the DMN in regulating hypophysiotropic TRH neurons 
remains uncertain, but may be implicit in the knowledge that the DMN also has an important 
role in the regulation of energy homeostasis (177).  Electrolytic and chemical (ibotenic acid) 
lesions of the DMN results in hypophagia due to an altered setpoint of body weight regulation 
(177).  The DMN likely has both orexigenic and anorexigenic neuronal populations, however, 
as DMN lesions also increase food intake during the first hour of refeeding after a period of 
fasting, and attenuate CCK-induced decrease in food intake (177). 
    As the DMN contains leptin-, insulin- and ghrelin-receptive and glucosensing neurons (70, 
177-179), some of these neurons may function to transmit humoral signals to TRH neurons in 
the PVN.  However, it is unlikely that the DMN functions independently of the arcuate 
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nucleus in the regulation of hypophysiotropic TRH neurons, at least during fasting, as animals 
deficient in arcuate nucleus NPY and melanocortin peptides lose the ability to induce central 
hypothyroidism in response to fasting (112, 151).  
    Neurons of the DMN, however, receive feeding-related inputs from the arcuate nucleus, 
and are densely innervated by both AGRP- and α-MSH-containing axons (71, 180).  
Furthermore, the majority of DMN neurons that project to the PVN receive melanocortin 
input from the arcuate nucleus (71).  This circuitry indicates that the DMN may serve as a 
relay station from the arcuate nucleus to the PVN, contributing to the effects of melanocortin 
signaling on the hypophysiotropic TRH neurons (71).  
    In addition to the regulation of food intake, the DMN is also involved in circadian 
regulation of hypothalamic systems (181).  The DMN receives both direct and indirect inputs 
from the SCN, and ablation of the DMN reduces the circadian rhythm of wakefulness, 
feeding, locomotor activity, and the hypothalamic-pituitary-adrenal (HPA) axis (181).  The 
DMN, therefore, may integrate feeding and circadian rhythm-related signals involved in the 
regulation of the HPT axis.  In fact, the DMN is known to be a critical regulator of food-
entrainable circadian rhythm of several hypothalamic systems (182).  Fasting blunts the 
nocturnal increase of TSH secretion in humans (183), but it is unclear yet whether the DMN is 
involved in this process. 
    Hypophysiotropic TRH neurons also receive dense input from the brainstem that contains 
feeding related peptides such as NPY and CART (64, 80).  These inputs, however, do not 
seem to have a role in the fasting-induced regulation of TRH neurons, because transection of 
ascending brainstem pathways does not affect fasting-induced inhibition of TRH gene 
expression in hypophysiotropic neurons (unpublished personal observations). 
 
V. Effects of dehydration-induced anorexia on the hypothalamic-pituitary-thyroid axis 
38 
 
    Dehydration induced by replacement of drinking water with 2.5% NaCl,  gradually 
decreases daily food intake by 80-90% and is associated with significant weight loss despite 
the fact that the animals have free access to food (184).  This experimental model, commonly 
referred to as dehydration induced anorexia (DIA), has been used by researchers to explore 
central mechanisms involved in the regulation of anorexia (184).  Of interest, while food 
restriction inhibits all components of the HPT axis, DIA is accompanied by an increase in 
TRH gene expression in the PVN, elevated circulating TSH levels, yet unaltered T4 and 
decreased T3 concentrations in the peripheral blood (185).  The increase in TSH 
concentration is likely secondary to increased TRH release, while the low T3 level may be 
secondary to increased peripheral T3 metabolism or clearance.  
    The effect of DIA on TRH neurons in the PVN, however, is not uniform (186).  Similar to 
fasting, TRH mRNA is decreased in the mid level of the PVN (186), raising the possibility 
that these neurons are regulated by the arcuato-paraventricular pathway.  Hypophysiotropic 
TRH neurons in the caudal part of the PVN, however, are stimulated by DIA, while inhibited 
in food restricted animals (186), indicating that any inhibitory effect of the arcuato-
paraventricular pathway is overridden by other factors.  Since the TSH concentration is 
increased in DIA animals (185), it is likely that stimulation of the caudal TRH cell group and 
inhibition of the mid level TRH cell population in the PVN results in a net increase of TRH 
release into the hypophysial portal circulation.  
    One, major difference between the peptide expression profile of the food restricted and 
DIA animals is increased CRH expression in lateral hypothalamic neurons in DIA animals 
(184).  These CRH neurons are known to project to the PVN (184) and may contribute to the 
innervation of TRH neurons in the PVN (86).  In support of this hypothesis, CRH stimulates 
TRH biosynthesis, and administration of a CRH-R2 antagonist prevents DIA-induced effects 
on TRH gene expression in the PVN (187). 
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    In addition to the caudal part of the PVN, DIA also stimulates TRH neurons in the anterior 
parvocellular subdivision of the PVN (186).  These neurons are not involved in the regulation 
of the HPT axis (58).  Nevertheless, since the central administration of TRH inhibits food 
intake (188) and TRH neurons in the anterior PVN project to brain nuclei that are involved in 
the regulation of food intake (54), it is possible that the increased activity of TRH neurons in 
the anterior PVN contributes to the anorexigenic effect of DIA.   
 
VI. Regulation of the HPT axis in high fat diet-induced obese animals 
    Consumption of high fat diet (HFD) results in increased caloric intake, increased weight 
gain and also a stimulation of the HPT axis, characterized by increased TRH mRNA and 
protein levels in the PVN and TSH and thyroid hormone levels in the circulation (170).   
Since the HFD-induced obese (DIO) animals have elevated leptin levels, and the HFD does 
not stimulate the HPT axis in leptin deficient ob/ob mice (170), the effect of HFD on the HPT 
axis seems to be mediated by leptin (170).  However, expression of the proopiomelanocortin 
(POMC, the precursor of α-MSH) gene in the arcuate nucleus of DIO rats remains unchanged 
(189), suggesting that HFD decreases leptin sensitivity of anorexigenic neurons in this 
nucleus.  This concept is supported by decreased STAT3 phosphorylation and increased 
SOCS3 and PTP1B synthesis in the arcuate nucleus of HFD animals after leptin treatment 
(190, 191).  
    Therefore, in contrast to fasting, leptin would appear to regulate the HPT axis 
independently from POMC neurons.  Since central leptin administration results in STAT3 
phosphorylation in hypophysiotropic TRH neurons in DIO rats, it is hypothesized that the 
HPT axis is regulated by a direct action of leptin on these neurons (170).  However, leptin-
induced regulation of AGRP synthesis in the arcuate nucleus and the leptin sensitivity of 
neurons in the dorsomedial nucleus remain intact in DIO animals (189, 190), necessitating the 
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need for additional studies to exclude the possibility that the effect of leptin on 
hypophysiotropic TRH neurons in DIO animals is mediated indirectly by these neuronal 
groups.  
 
VII. Central regulation of the HPT axis during infection and prolonged critical illness 
    Similar to fasting, infection and other acute and chronic disorders can lead to inhibition of 
the HPT axis.  In man, this condition is commonly referred to as the non-thyroidal illness 
syndrome (192) and is discussed in further detail in section IX.  Characteristic of this 
syndrome is a decline in circulating T3, and in more severe cases, a general inhibition of the 
HPT axis due to the development of central hypothyroidism (192-194).  
 
a. Role of neuronal pathways in the regulation of hypophysiotropic TRH neurons during 
infection 
    A commonly used model for infection is the peripheral administration of bacterial 
lipopolysaccharide (LPS).  However, while both fasting and LPS administration have a 
similar effect to induce central hypothyroidism, the mechanisms by which these two 
conditions influence the hypophysiotropic TRH neurons are different.  As discussed 
previously, the fall in the circulating level of leptin orchestrates the inhibitory effect of fasting 
on hypophysiotropic TRH neurons via the arcuato-paraventricular pathway (37, 58).  In 
contrast, LPS treatment increases circulating leptin levels (58, 195), stimulates POMC and 
CART gene expression in arcuate nucleus neurons, and does not increase NPY expression 
(195, 196), changes that would predict activation of hypophysiotropic TRH neurons rather 
than suppression as observed (37, 58, 194, 197).  Presumably, therefore, a more potent, 
inhibitory mechanism becomes activated during infection that overrides any stimulatory 
action of leptin, α-MSH or CART on hypophysiotropic TRH neurons. 
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    One possibility to explain the effect of LPS on hypophysiotropic TRH neurons is activation 
of adrenergic neurons in the medulla, as these neurons are known to mediate the effect of LPS 
on CRH neurons in the PVN and result in a marked increase in circulating levels of 
corticosterone (198).  As described above, medullary adrenergic neurons directly innervate 
hypophysiotropic TRH neurons (77).  Unilateral transection of ascending brainstem pathways 
or ablation of the catecholaminergic input of the PVN which markedly attenuates LPS-
induced c-Fos expression in the PVN and the increase in CRH gene expression (198, 199), 
however, results in an even more profound inhibition of TRH gene expression in the PVN 
(199).  Thus, brainstem inputs would appear to stimulate rather than inhibit hypophysiotropic 
TRH neurons during infection, and in keeping with the activating effects of catecholamines 
on hypophysiotropic TRH (78).   
 
b. Tanycytes as key regulators of hypophysiotropic TRH neurons during infection 
    LPS has a potent effect on tanycyte D2 gene expression and enzymatic activity, resulting in 
an approximately four-fold increase of D2 mRNA level and activity in the MBH within 12 
hours of administration (Fig. 15 A, B) (197, 200).  It has been hypothesized, therefore, that 
LPS may inhibit hypophysiotropic TRH neurons by increasing local T3 levels in the median 
eminence, where the processes of β tanycytes and the axon terminals of the hypophysiotropic 
TRH neurons are closely associated (51, 99).  In support of this hypothesis, LPS-induced 
inhibition of hypophysiotropic TRH neurons is abolished in the D2 knock out mice (201).  
While D2 activity rapidly increases in tanycytes and is maximal 9-12h after LPS treatment, 
D2 activity gradually increases in other responsive tissues such as the cortex and the anterior 
pituitary, and becomes maximal at approximately 24h (99, 202).  This difference in the D2 
response favors distinct, tissue-specific mechanisms for activation of D2.  The increase in D2 
activity in the cortex and anterior pituitary is inversely related to peripheral thyroid hormone 
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levels and can be prevented by clamping circulating T4 to euthyroid levels (99, 197).  This 
indicates that in the cortex and anterior pituitary, D2 activation is secondary to LPS-induced 
reduction in peripheral thyroid hormone levels.  The T4 clamp, however, has no effect on the 
LPS-induced increase in D2 activity in the tanycytes (197).  
    The mechanism by which LPS stimulates D2 activity in tanycytes remains uncertain.  One 
attractive possibility includes a direct action of LPS on tanycytes via their expression of Toll-
like receptor 4 (TLR4) (203), as lack of TLR4 in TLR4 knock out mice prevents the LPS 
induced non-thyroidal illness syndrome (204).  The main second messenger utilized by TLR4 
and many of the cytokine receptors is the NF-κB system (205), and, the promoter of the D2 
gene is highly responsive to NF-κB (99, 206).  The human D2 gene contains two, high 
affinity, NF-κB binding sites at positions -683bp (called no.2) and -198bp (no. 5), 5’ to the 
transcriptional starting site (206).  Although both sites have a similar binding affinity by 
EMSA assay, site-directed mutagenesis and promoter assay indicates that only site no. 5 
possesses transactivation potency in the presence of the p65 subunit of NF-κB, increasing D2 
promoter activity 150-fold (206).  However, LPS-induced activation of IκBα mRNA, a 
marker of NF-κB signaling, is observed only in a subset of  tanycytes and only 12h after 
LPS administration (Fig. 15 C-E), significantly later than the peak of the LPS-induced 
increase in D2 mRNA in these cells (142, 202).  Thus, LPS-induced NF-B activation via 
TLR4 or other cytokine receptors seem less likely the initial stimulus that increases D2 
activity in tanycytes in response to LPS treatment, and rather may be involved  in the 
maintenance of increased D2 (142).  
    IκBα mRNA, however, markedly increases in the pars tuberalis of the pituitary gland 3h 
after LPS treatment (Fig. 15 D) (142), a portion of the pituitary that is immediately adjacent to 
tanycyte end-feet processes in the external zone of the median eminence and in the sulcus 
tuberoinfundibularis (207).  The pars tuberalis contains a large number of TSH-producing 
43 
 
cells, but in contrast to thyrotropes in the anterior pituitary, TSH-producing cells of the pars 
tuberalis are not affected by TRH or thyroid hormone (207).  Since the synthesis of TSHβ 
subunit increases significantly in these cells 9h after LPS treatment (Fig. 15 F, G) (142), and 
the TSH receptor is expressed in tanycytes (103), TSH secretion from the pars tuberalis may 
be involved in mediating the effects of LPS on the tanycytes.  Indeed, TSH has been shown to 
increase D2 activity in these cells via activation of cAMP (208).  In addition, CREB 
phosphorylation, a marker of increased cAMP production, is evident in tanycytes 9h after LPS 
administration (Fig. 15 H) when D2 synthesis peaks, but absent from tanycytes at 6h after 
LPS administration when D2 synthesis is already increased (142). 
    The effect of LPS on the tanycytes, therefore, may be mediated by at least three factors.  
The first factor is responsible for early increase in D2, but remains unknown.  TSH released 
from the pars tuberalis may then contribute to enhancing D2 activation shortly thereafter, 
followed by other factors that maintain D2 activity by stimulating NF-κB signaling in 
tanycytes.  While changes in circulating levels of corticosterone have been suggested to have 
a role in the stimulation of D2 activity in fasted animals (171), a corticosterone clamp in 
adrenalectomized animals does not prevent the LPS-induced increase of D2 activity (202) nor 
influence LPS-induced inhibition of TRH synthesis (194). 
 
c. Regulation of hypophysiotropic TRH neurons during prolonged critical illness 
    The effect of prolonged critical illness on the HPT axis has been studied in a rabbit model 
using third-degree burn injury (209, 210).  As in infection, prolonged critical illness results in 
low T4, T3 and TSH concentration in the circulation and decreased TRH mRNA level in the 
PVN (209, 210).  In addition, it is associated with increased D2 gene expression in the MBH 
(210), indicating that similar to infection, burn injury may inhibit the HPT axis by inducing 
local hypothalamic hyperthyroidism caused by the increased thyroid hormone activating 
44 
 
capacity of tanycytes.  Comparison of the T3 content in whole hypothalamic blocks of healthy 
and ill rabbits did not support this hypothesis, however, as T3 levels were not found to be 
higher in the experimental animals (210).  Nevertheless, the approach did not take into 
account that burn-induced tissue hyperthyroidism may take place in only focal regions of the 
hypothalamus such as the median eminence and paraventricular nucleus, which may be 
sufficient to inhibit hypophysiotropic TRH neurons.   
    Prolonged illness is also accompanied by a nutritional deficit, raising the possibility that the 
decreased calorie intake also contributes to the development of central hypothyroidism during 
prolonged critical illness (209).  Early parenteral nutrition, however, does not influence the 
illness-induced decrease in TRH gene expression and the decline in circulating level of T4 
(209).  The expected decline in the circulating level of T3 was prevented, however, suggesting 
that the nutritional deficit may have its greatest influence on thyroid hormone metabolism in 
peripheral tissues (209). 
 
VIII. Regulation of hypophysiotropic TRH neurons by cold exposure and suckling 
    Thyroid hormone has a critical role in the regulation of both obligatory and adaptive 
thermogenesis (211).  In the presence of hypothyroidism, obligatory thermogenesis, the heat 
dissipated due to the biochemical processes necessary for the maintenance of life, is reduced 
by approximately 30% (211).  Hypothyroidism also interferes with adaptive thermogenesis, 
required to maintain normal body temperature in a cold environment (211).  It is not 
surprising, therefore, that cold exposure serves as an important stimulus for TRH gene 
regulation in the PVN to increase thyroid hormone levels (212).  The increase in TRH mRNA 
by cold exposure is transient, however, increasing by 100% within 1h of the cold exposure, 
followed by a decline to normal levels during the second hour (213).  Peak TRH release from 
the median eminence also occurs 40 minutes after the cold exposure (213), and is facilitated 
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by a cold-induced increase in the synthesis of prohormone convertase enzymes, PC1/3 and 
PC2, involved in the processing of proTRH (214). 
    The physiological role of this early, transient increase in thyroid hormone levels is not 
completely clear.  Cold exposure markedly increases D2 activity in BAT (94).  As a result, 
thyroid hormone receptors are fully occupied by T3 in the BAT after 4h of cold exposure 
(211) when the thyroid hormone levels have already normalized after a transient increase.  In 
addition, administration of low doses of T4 to thyroidectomized rats can completely 
normalize the thermogenesis without normalizing the thyroid hormone concentration in the 
circulation (215), suggesting that even low circulating levels of thyroid hormone are sufficient 
for normal thermogenesis.  We hypothesize, therefore, that the cold-induced transient increase 
in thyroid hormone may be necessary to initiate thermogenesis in BAT before D2 activity is 
sufficiently increased to maintain BAT thermogenesis, even without increased thyroid 
hormone levels in the circulation.  This hypothesis, however, requires further clarification.   
    As central administration of TRH stimulates thermogenesis in BAT via the activation of the 
sympathetic nervous system (57), the cold-induced increase in TRH gene expression in the 
PVN might be hypothesized to increase heat production in BAT simultaneously with 
stimulation of the HPT axis.  Indeed, TRH has been shown to stimulate the BAT after its 
administration into the DMN, preoptic area, hypothalamic ventromedial nucleus (VMN), 
anterior hypothalamus or hindbrain (57, 216).  However, as none of these brain regions are 
innervated by hypophysiotropic TRH neurons (unpublished observations), the effect of TRH 
on BAT is likely mediated by other groups of TRH-synthesizing neurons. 
    The effect of cold on the activity of hypophysiotropic TRH neurons is thought to be 
mediated primarily by the brainstem catecholaminergic neurons, because noradrenaline 
stimulates TRH synthesis (78) and inhibition of noradrenaline prevents cold-induced 
activation of the HPT axis (217).  In addition, the HPT axis does not respond to cold during 
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the first, ten, postnatal days in rodents during which time catecholaminergic axons are still 
migrating to TRH neurons in the PVN (1).  Furthermore, inhibition of adrenergic receptors 
blocks cold-induced TRH synthesis and release (214, 218). 
    Cold stimulates TRH gene expression, biosynthesis and proteolytic processing via β 
adrenergic receptors, and by increasing cAMP production (214).  Both adrenergic and 
noradrenergic brainstem neurons densely innervate hypophysiotropic TRH neurons in the 
PVN (61), but the A2 noradrenergic cell group is the only catecholaminergic population in 
which cold-induced c-Fos activation can be observed.  The release of TRH is also stimulated 
by cold via α adrenergic receptors (214, 218).  This effect is independent of the regulation of 
TRH synthesis (214, 218).   
    Similar to cold exposure, suckling also stimulates TRH gene expression (213, 219).  TRH 
mRNA is increased in the PVN during the first days of lactation, but then declines after the 8
th
 
day (219).  Acute suckling also results in a 2-fold increase in TRH mRNA in the PVN after 30 
min of suckling, that gradually decreases to presuckling levels after 6h (213, 219).  This 
response is associated with increased prolactin levels in the circulation, but surprisingly, with 
unaltered TSH and thyroid hormone levels (219, 220).  The mechanism for suckling-induced 
activation of hypophysiotropic TRH neurons is currently unclear, but the differential response 
of the anterior pituitary to TRH is likely mediated by several factors.  Corticosterone may be 
important in the prevention of TRH-induced TSH secretion, as corticosterone-clamped, 
adrenalectomized animals increase TSH in response to suckling (219).  A decline in dopamine 
release in response to suckling may also contribute to the increased sensitivity of lactortophs 
to TRH (47).  CART, co-synthesized in hypophysiotropic TRH neurons, has been shown to 
modulate the effect of TRH on lactortophs, preventing TRH from releasing prolactin without 
influencing TSH release during cold exposure and in association with hypothyroidism (220, 
221).  As opposed to cold exposure and hypothyroidism when CART is increased in 
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hypophysiotropic neurons (220), CART remains unchanged during suckling in 
hypophysiotropic neurons, potentially favoring the release of prolactin (220). 
 
IX. Translational ramifications 
    Because of the similarities between the anatomical organization of the hypophysiotropic 
TRH-synthesizing neuronal system in experimental animals and man (see above), it is 
reasonable to assume that regulation of the HPT axis in man may have similarities to that 
observed in rodents.  In support of this hypothesis, the important role of TRH in the regulation 
of anterior pituitary TSH secretion in man is suggested by the presence of central 
hypothyroidism associated with mutations in the TRH receptor gene.  Namely, individuals 
homozygous for TRH receptor mutations or compound heterozygotes demonstrate low levels 
of total and free T4, and have inappropriately low or normal TSH levels (222, 223).  In 
addition, their TSH secretion is not influenced by exogenous administration of TRH (222, 
223)..  Hence, although these individuals are able to produce TSH, the biological activity of 
their TSH is decreased, and they regulate TSH secretion at a lower set point, presumably due 
to deficiency in TRH signaling, resulting in lower than normal circulating levels of T4 (222, 
223). 
    As in  rodents, feedback regulation of the HPT axis in man would also appear to require the 
MCT8 thyroid hormone transporter.  This is apparent in the Allan-Herndon-Dudley 
syndrome, secondary to mutations in MCT8, characterized by elevations in T3, a low T4 level 
and a circulating TSH level in the upper normal range (224, 225).  Although one might have 
anticipated a greater elevation in TSH if MCT8 has an important role in the transport of 
thyroid hormone to hypophysiotropic TRH neurons in man, these patients can have a blunted 
response to exogenously administered TRH (226), indicating that anterior pituitary 
thyrotropes may still retain the ability to transport T3 through other mechanisms, diminishing 
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the direct stimulatory effect of TRH.  Negative feedback inhibition of the HPT axis by thyroid 
hormone would also appear to be primarily mediated by TR in man, as individuals with 
mutations in TR show major abnormalities in circulating thyroid hormone levels and have 
inappropriately elevated TSH level (227)  In contrast, whereas mutation of TRα is associated 
with clinical signs of severe hypothyroidism, it results in slightly low circulating levels of T4 
and normal levels of T3 and TSH (228).  This observation is also consistent with the concept 
that TR1 may have an activating effect on the synthesis of TRH in hypophysiotropic TRH 
neurons (see above, Section III)  
    Leptin is also likely to have an important role in the regulation of the thyroid axis in man, 
as suggested by the close correlation between the circadian rhythm of leptin secretion and 
TSH (229).  Circulating levels of both hormones are the highest between midnight and early 
morning and lowest in the early to mid-afternoon (229).  In addition, subjects with congenital 
leptin deficiency, due to mutations in the leptin gene, have impaired thyroid function 
characterized by low levels of T4, inappropriately normal levels of TSH, disregulation of TSH 
pulsatility and circadian rhythms, and/or an exaggerated response to exogenously 
administered TRH that is a characteristic feature of central hypothyroidism (229, 230). The 
thyroid phenotype, however, tends to be heterogeneous among the various families described 
(229, 230).  In the Pakistani family with leptin deficiency reported by Montague et al (231), 
leptin replacement therapy significantly increased their T3 and T4 levels that were maintained 
at these higher levels with continued leptin treatment (232).  Leptin also appears to orchestrate 
the suppression in circulating thyroid hormone levels during fasting and other disorders 
associated with a reduction in caloric intake in man such as hypothalamic amenorrhea and 
eating disorders.  Leptin administration to normal individuals undergoing a 3 day fast restored 
fasting-induced effects on TSH pulsatility and increased T4 levels (233).  In addition, leptin 
administration to individuals undergoing a more prolonged period of a less severe caloric 
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restriction prevented the fall in T3 and T4 levels (234), although a similar response was not 
observed in a separate study working with obese patients (235).  Leptin and thyroid hormone 
levels also tend to be low in individuals with hypothalamic amenorrhea induced by strenuous 
exercise and eating disorders (236).  These alterations can be reversed with leptin replacement 
(237).  Although there has been a reluctance to use leptin to treat patients with anorexia 
nervosa due to its suppressive effects on appetite and to increase energy expenditure, a 
correlation between low thyroid hormone and leptin levels is also well described in this 
disorder (238). Presumably, as in rodents, this response is homeostatic to reduce energy 
expenditure.  Whether leptin is also responsible for increases in thyroid hormone levels 
observed in obese individuals is uncertain, but a correlation between increased leptin levels 
and higher T3 and TSH levels has been observed in obese patients (239).  
    A somewhat more complex issue is whether leptin is involved in the development of the so-
called “nonthyroidal illness syndrome” or “euthyroid sick syndrome”, observed in 
approximately 40-70% of patients with severe illness in intensive care settings (240, 241).  
Low circulating levels of thyroid hormones but seemingly inappropriately low or normal TSH 
levels, diminished TSH pulsatility and decreased TRH gene expression in the paraventricular 
nucleus are observed, suggesting the presence of central hypothyroidism, but the changes are 
completely reversible when the patient recovers (193, 240, 241).  The decrease in thyroid 
hormone levels may be a homeostatic response to conserve energy stores under these adverse 
conditions and consistent with the physiology described above in experimental animals and 
human subjects associated with fasting.  In support of this hypothesis, recent studies by 
Casaer et al (242) and Langouche et al (243) have demonstrated that early nutrient restoration 
to patients with critical illness in an intensive care unit setting is associated with greater 
complications and a more prolonged hospitalization.  A very low T4 level, however, is 
predictive of poor outcomes in the intensive care unit setting, and perhaps an even better 
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indicator of the severity of illness than the APACHE II score (244, 245).  When T4 falls to 
less than 4 g/dl, the risk of death rises to ~50%, and when T4 falls to <2 g/dl, mortality 
increases even more to ~80% (246-248).  Thus, when T4 begins to decline, it remains unclear 
whether this is the progression of an adaptive response and does not require therapy, or 
whether it is indicative of a maladaptive response and should be vigorously treated to restore 
circulating thyroid hormone levels to normal.  Evidence that the mechanisms for central 
hypothyroidism associated with infection is vastly different than that elucidated associated 
with fasting, cited in section VII, would give credence to the concern that the nonthyroidal 
illness syndrome associated with severe illness may not be a homeostatic mechanism 
mediated by leptin but, in fact, maladaptive and pathophysiologic (246).  Namely, central 
hypothyroidism may be an epiphenomenon of infection-induced upregulation of type D2 
deiodinase in tanycytes causing hypothalamic hyperthyroidism and not part of an intended, 
homeostatic, physiologic response to reduce metabolic rate and energy expenditure to 
promote survival.  
    A number of small clinical trials have attempted to determine whether thyroid hormone 
replacement in intensive care unit patients has any beneficial or detrimental effects on overall 
outcomes (246, 247, 249).  Most of these studies have shown T4 or T3 to be safe and well 
tolerated (250, 251).  Improvement in cardiac hemodynamic parameters including cardiac 
output, end diastolic volume and stroke volume, and a reduction in peripheral arterial 
resistance have been observed in patients receiving T3 following coronary artery bypass 
surgery and/or in patients with dilated cardiomyopathy (249, 252-255), but at the expense of 
further suppression in circulating levels of TSH.  However, other studies have not found a 
benefit as summarized by Kaptein et al (256).  It could be argued, however, that because of 
the associated rise in D1 and D3 in peripheral tissues in these patients (257), neither T4 nor 
T3 is appropriate therapy due to the effects of these enzymes to increase the conversion of T4 
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to reverse T3 (rather than T3) or degrade T3, respectively (246).  The appropriate studies to 
determine whether correcting the HPT axis to normal in patients with severe illness, therefore, 
have not been conducted.  A novel approach for the treatment of the nonthyroidal illness 
syndrome in critically ill patients has recently been suggested by Van den Berghe et al (258, 
259).  Using a continuous infusion of TRH together with a growth hormone secretagogue 
restored thyroid hormone levels and TSH pulsatility in these patients, and also improved 
catabolic parameters.  However, carefully controlled studies are needed to determine whether 
this approach is associated with improved outcomes and reduced mortality. 
 
X. Conclusion 
    Maintenance of circulating levels of thyroid hormones is controlled by what is classically 
called a “simple” negative feedback mechanism exerted on hypophysiotropic TRH neurons in 
the PVN.  This regulatory mechanism, however, is vastly more complex, being modulated by 
glial-neuronal and neural-neural interactions as well as other circulating, humoral substances 
such as leptin.  Given that hypophysiotropic TRH neurons are innervated by axons containing 
multiple peptides whose origin and physiological significance has not yet been determined 
(see Fig. 6), it is likely that the regulatory mechanisms involved are even more complex.  
Presumably, this finely tuned machinery provides flexibility to the HPT axis, enabling 
continuous adaptation to the constantly changing internal and external milieu.  In most 
situations, alterations in the setpoint for negative feedback regulation would appear to be 
adaptive, contributing to the optimization of energy homeostasis.  Elucidation of the basic 
mechanisms involved in central regulation of the thyroid axis, however, raise questions as to 
whether under certain circumstances, such as prolonged critical illness, regulation of the HPT 
axis may be maladaptive.  Further research to elucidate the neurobiology involved in central 
regulation of hypophysiotropic TRH neurons will be instrumental in understanding how these 
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disorders give rise to alterations in the HPT axis and to facilitate the appropriate approach to 
therapy. 
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Figure Legends 
Figure 1.  Schematic illustration of the organization of the rat preproTRH gene.  
 
Figure 2.  Distribution of TRH-synthesizing neurons in the rat PVN.  (A-C) Low power 
micrographs illustrate the TRH neurons at three rostrocaudal levels of the PVN.  Schematic 
drawings (D-F) illustrate the subdivisions of the PVN where hypophysiotropic TRH neurons 
are localized (gray).  AP, anterior parvocellular subdivision; DP, dorsal parvocellular 
subdivision; LP, lateral  parvocellular subdivision; MN, Magnocellular part of PVN; MP, 
medial parvocellular subdivision, PV, periventricular parvocellular subdivision, III, third 
ventricle (From Fekete and Lechan (58), copyright 2007, with permission from Elsevier.) 
 
Figure 3. Darkfield photomicrographs showing proTRH mRNA expression in the anterior-, 
mid- and posterior levels of the PVN in (A-C) control and (D-F) hypothyroid rats, and (G-I) 
control and (J-L) hypothyroid mice.  Note dramatic increase of in silver grains denoting 
proTRH mRNA in the mid and caudal level of the hypothyroid rat PVN (E, F), while 
hypothyroidism increases proTRH mRNA only in mid-level neurons in mice (K).  III, third 
ventricle.  (G-L are from Kádár et al. (44), copyright 2010, with permission from Wiley-Liss 
Inc.)   
 
Figure 4. Distribution of TRH-immunoreactive (IR) terminals in the mouse median 
eminence.  TRH-IR axons densely innervate the external zone of the median eminence.  III, 
third ventricle; ME, median eminence 
 
Figure 5. Innervation of the TRH neurons in the rat PVN from neurons originating in the (A) 
arcuate nucleus , (B) DMN and (C) catecholaminergic neurons in the brainstem.  In (A) TRH 
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neurons (blue) are contacted by axon terminals containing α-MSH (red; arrowhead) and 
AGRP (green; arrows).  In (B), axon varicosities containing the anterogradely transported 
marker protein, PHA-L (black) are juxtaposed to TRH-synthesizing neurons (brown) after 
iontophoretic administration of the tracer into the DMN.  In (C), both noradrenergic- (red, 
open arrows) and adrenrenergic-containing (yellow, white arrows) axons establish contacts 
with the TRH neurons.  (Modified from Fekete et al. (52), Mihaly et al. (74), copyright 2001, 
with permission from Elsevier; and Fuzesi et al. (61), copyright 2009, with permission from 
Elsevier) 
 
Figure 6.  Schematic drawing summarizing known inputs to TRH neurons in the PVN.  The 
inputs with identified origins are depicted by a neuron sending its axon to the TRH neuron.  
Inputs with currently unknown origins are labeled with axon terminals on the surface of the 
TRH neuron.  
 
Figure 7.  (A,B) Organization of tanycyte subtypes in the mediobasal hypothalamus.  (A) 
Vimentin-immunolabeled (red) coronal section with DAPI counterstaining (blue) shows the 
distribution of tanycytes and their processes.  The schematic diagram (B) illustrates the 
location of tanycyte subtypes in the wall and floor of the third ventricle.  All tanycyte 
subtypes synthesize (C) MCT8, and (D) OATP1C1 thyroid hormone transporters.  In (E) 
silver grains denoting type 2 deiodinase mRNA are accumulated over the cells lining the wall 
of the third ventricle, the tuberoinfundibular sulci (arrow heads) and around blood vessels in 
the arcuate nucleus (arrows).  Higher power micrographs shows the association of D2 mRNA 
with (F) the tuberoinfundibular sulcus (arrow heads) and a blood vessel (arrows) in the 
arcuate nucleus, and (G) in the external zone of the median eminence.  (H) Tanycyte 
expression of pyroglytamyl peptidase II (PPII) mRNA.  III, third ventricle; Arc, arcuate 
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nucleus, DMN, hypothalamic dorsomedial nucleus; ME, median eminence; VMN, 
ventromedial nucleus. (Modified from Sanchez et al. (35); Kalló et al. (51); Fekete et al. 
(124), copyright 2000, with permission from Elsevier; (E) courtesy of Dr. Gábor Wittmann)  
 
Figure 8.  In situ hybridization autoradiograms showing the effect of hypo- and 
hyperthyroidism on proTRH mRNA level in the medial parvocellular subdivision of the PVN.  
A substantial increase in silver grain accumulation is observed in the (A) hypothyroid animal 
compared to the (B) fed control.  In contrast, hyperthyroidism results in a marked reduction of 
proTRH mRNA level in the PVN (C).  (From Dyess et al (115), and from Fekete and Lechan 
(58), copyright 2007, with permission from Elsevier.)) 
 
Figure 9.  In situ hybridization autoradiographs of proTRH mRNA in the paraventricular 
nucleus (PVN) of (A) hypothyroid, (B) euthyroid and (C,D) hypothyroid animals receiving a 
constant infusion of (C) 0.5 µg or (D) 0.75 µg of T3/100 gm/bw/d. Mean plasma 
triiodothyronine (T3) levels (±SEM) are shown for each group at the bottom of the 
photomicrographs.  Note that only the higher dose of T3 that raised plasma T3 levels into the 
supranormal range was capable of suppressing proTRH mRNA to euthyroid levels.  (E) 
Regression analysis of above experiment.  Interrupted line represents the mean ln(proTRH 
mRNA) for euthyroid animals, and its intercept with the regression line estimates the plasma 
T3 concentration required to suppress proTRH mRNA to euthyroid levels.  Ninety-five 
percent confidence intervals for each intercept are bracketed.  Open dots denote values for 
hypothyroid animals and hypothyroid animals infused with graded doses of T3.  Closed dots 
denote values for euthyroid controls.  (Modified from Kakucska et al (123), and from Fekete 
and Lechan (58), copyright 2007, with permission from Elsevier.)) 
 
Figure 10.  Schematic illustration of the machinery involved in negative feedback regulation 
of the HPT axis by thyroid hormone.  
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Figure 11.  Darkfield illumination photomicrographs of proTRH mRNA in the hypothalamic 
PVN in (A) fed, (B) fasted, and (C) fasted animals receiving leptin. Note the marked 
reduction in silver grains over neurons in the PVN in the fasted animals but restoration to 
normal in the fasted animals receiving leptin. III, third ventricle (From Fekete et al (155), and 
from Fekete and Lechan (58), copyright 2007, with permission from Elsevier.).) 
 
Figure 12.  Schematic drawing summarizing the regulation of TRH neurons by fasting.  
 
Figure 13. Darkfield illumination micrographs of proTRH mRNA in the medial and 
periventricular parvocellular subdivisions of the hypothalamic PVN in (A, D) fed, (B, E) 
fasted and (C,F) fasted animals receiving an intracerebroventricular infusion of either (C) α-
MSH  or (F) CART  every 6 hr for 64 hr.  Note the reduction in the accumulation of silver 
grains over the PVN in fasted animals compared with the fed controls.  Both α-MSH and 
CART administration prevent the fasting-induced fall of proTRH mRNA .  III, Third ventricle 
(From Fekete et al (42, 52), and from Fekete and Lechan (58), copyright 2007, with 
permission from Elsevier.) 
 
Figure 14.  Darkfield illumination photomicrographs of proTRH mRNA in the medial 
parvocellular subdivision of the PVN in (A) control, (B) AGRP- , and (C) NPY-treated 
animals.  Note marked reduction in silver grains over neurons in the PVN in both the AGRP- 
and NPY-infused groups.  III, Third ventricle (From Fekete et al (155), and from Fekete and 
Lechan (58), copyright 2007, with permission from Elsevier.) 
 
Figure 15.  (A,B) Regulation of type 2 deiodinase gene expression in tanycytes by LPS.  
Low-power darkfield micrographs of the caudal part of the hypothalamus showing the D2 
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expression in (A) control animals and (B) 12h after LPS administration.  Note marked 
increase in the density of silver grains, particularly in the external zone of the median 
eminence.  (C-E) Darkfield illumination photomicrographs of Iκ-Bα mRNA expression in the 
MBH in animals receiving (C) saline or LPS (D) 3 h, or (E) 12 h before sacrifice.  Note the 
marked accumulation of silver grains over the pars tuberalis (PT) in (D) 3 h after the 
administration of LPS.  Iκ-Bα mRNA is only seen in a subset of α tanycytes 12 h after LPS 
administration (arrows in E).  (F, G, arrows) Expression of TSHβ mRNA in the pars tuberalis 
(PT) of animals receiving (F) saline or (G) LPS 9h before sacrifice.  Note increased 
expression of TSHβ mRNA in the PT after LPS administration. Ventricular borders are 
demarcated with dotted lines.  Double-labeled fluorescent image (H) illustrates the presence 
of phospho-CREB (green, yellow, arrows) in the nucleus of tanycytes (red) 9h after 
administration of LPS.  III, Third ventricle; ME, median eminence; PT, pars tuberalis 
(Modified from fekete et al. (99); and Sanchez et al. (142).) 
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Conditions applicable to all Wiley Open Access articles:
The authors' moral rights must not be compromised. These rights include the
right of "paternity" (also known as "attribution" - the right for the author to
be identified as such) and "integrity" (the right for the author not to have the
work altered in such a way that the author's reputation or integrity may be
damaged). 
Where content in the article is identified as belonging to a third party, it is
the obligation of the user to ensure that any reuse complies with the
copyright policies of the owner of that content. 
If article content is copied, downloaded or otherwise reused for research and
other purposes as permitted, a link to the appropriate bibliographic citation
(authors, journal, article title, volume, issue, page numbers, DOI and the link
to the definitive published version on Wiley Online Library) should be
maintained. Copyright notices and disclaimers must not be deleted.
Creative Commons licenses are copyright licenses and do not confer any
other rights, including but not limited to trademark or patent rights.
Any translations, for which a prior translation agreement with Wiley has not
been agreed, must prominently display the statement: "This is an unofficial
translation of an article that appeared in a Wiley publication. The publisher
has not endorsed this translation." 
Conditions applicable to non-commercial licenses (CC BY-NC and CC
BY-NC-ND)
For non-commercial and non-promotional purposes individual non-
commercial users may access, download, copy, display and redistribute to
colleagues Wiley Open Access articles. In addition, articles adopting the CC
BY-NC may be adapted, translated, and text- and data-mined subject to the
conditions above.
Use by commercial "for-profit" organizations
Use of non-commercial Wiley Open Access articles for commercial,
promotional, or marketing purposes requires further explicit permission from
Wiley and will be subject to a fee. Commercial purposes include:
Copying or downloading of articles, or linking to such articles for further
redistribution, sale or licensing; 
Copying, downloading or posting by a site or service that incorporates
advertising with such content; 
The inclusion or incorporation of article content in other works or
services (other than normal quotations with an appropriate citation) that
is then available for sale or licensing, for a fee (for example, a
compilation produced for marketing purposes, inclusion in a sales pack) 
Use of article content (other than normal quotations with appropriate
citation) by for-profit organizations for promotional purposes 
Linking to article content in e-mails redistributed for promotional,
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the CC BY-NC-ND License requires consent which can be requested
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